EP1723121B1 - 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors - Google Patents

1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors Download PDF

Info

Publication number
EP1723121B1
EP1723121B1 EP05707386A EP05707386A EP1723121B1 EP 1723121 B1 EP1723121 B1 EP 1723121B1 EP 05707386 A EP05707386 A EP 05707386A EP 05707386 A EP05707386 A EP 05707386A EP 1723121 B1 EP1723121 B1 EP 1723121B1
Authority
EP
European Patent Office
Prior art keywords
phenyl
group
trifluoromethyl
substituted
mmol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Not-in-force
Application number
EP05707386A
Other languages
German (de)
French (fr)
Other versions
EP1723121A1 (en
Inventor
Heike Gielen-Haertwig
Barbara Albrecht
Jörg Keldenich
Volkhart Li
Josef Pernerstorfer
Karl-Heinz Schlemmer
Leila Telan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Priority to EP05707386A priority Critical patent/EP1723121B1/en
Publication of EP1723121A1 publication Critical patent/EP1723121A1/en
Application granted granted Critical
Publication of EP1723121B1 publication Critical patent/EP1723121B1/en
Anticipated expiration legal-status Critical
Not-in-force legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Definitions

  • the present invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.
  • the fibrous protein elastin which comprises an appreciable percentage of all protein content in some tissues, such as the arteries, some ligaments, the lungs and the heart, can be hydrolysed or otherwise destroyed by a select group of enzymes classified as elastases.
  • Human leukocyte elastase HLE, EC 3.4.21.37
  • HNE human neutrophil elastase
  • PMN polymorphonuclear leukocytes
  • HNE is capable of degrading a wide range of matrix proteins including elastin and collagen, and in addition to these actions on connective tissue HNE has a broad range of inflammatory actions including upregulation of IL-8 gene expression, oedema formation, mucus gland hyperplasia and mucus hypersecretion. It also acts as a mediator of tissue injury by hydrolysing collagen structures, e.g. in the heart after acute myocardial infarction or during the development of heart failure, thus damaging endothelial cells, promoting extravasation of neutrophils adhering to the endothelium and influencing the adhesion process itself.
  • HNE Pulmonary diseases where HNE is believed to play a role include lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, including smoking-induced emphysema, chronic obstructive pulmonary diseases (COPD) and cystic fibrosis.
  • ARDS acute respiratory distress syndrome
  • COPD chronic obstructive pulmonary diseases
  • cystic fibrosis In cardiovascular diseases, HNE is involved in the enhanced generation of ischaemic tissue injury followed by myocardial dysfunction after acute myocardial infarction and in the remodelling processes occurring during the development of heart failure. HNE has also been causally implicated in rheumatoid arthritis, atherosclerosis, brain trauma, cancer and related conditions in which neutrophil participation is involved.
  • inhibitors of HLE activity can be potentially useful in the treatment of a number of inflammatory diseases, especially of chronic obstructive pulmonary diseases [ R.A. Stockley, Neutrophils and protease/antiprotease imbalance, Am. J. Respir. Crit. Care 160, S49-S52 (1999 )].
  • Inhibitors of HLE activity can also be potentially useful in the treatment of acute myocardial syndrome, unstable angina pectoris, acute myocardial infarction and coronary artery bypass grafts (CABG) [ C.P. Tiefenbacher et al., Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart, Eur. J. Physiol.
  • WO 03/053930 describes 1,4-bis(hetero)aryl-dihydropyridines useful as HNE inhibitors, particularly in the treatment of chronic obstructive pulmonary diseases.
  • the present invention relates to compounds of the general formula (I) wherein
  • the compounds according to this invention can also be present in the form of their salts, hydrates and/or solvates.
  • Physiologically acceptable salts are preferred in the context of the present invention.
  • Physiologically acceptable salts according to the invention are non-toxic salts which in general are accessible by reaction of the compounds (I) with an inorganic or organic base or acid conventionally used for this purpose.
  • Non-limiting examples of pharmaceutically acceptable salts of compounds (I) include the alkali metal salts, e.g.
  • the alkaline earth metal salts such as magnesium and calcium salts
  • the quaternary ammonium salts such as, for example, triethyl ammonium salts, acetates, benzene sulphonates, benzoates, dicarbonates, disulphates, ditartrates, borates, bromides, carbonates, chlorides, citrates, dihydrochlorides, fumarates, gluconates, glutamates, hexyl resorcinates, hydrobromides, hydrochlorides, hydroxynaphthoates, iodides, isothionates, lactates, laurates, malates, maleates, mandelates, mesylates, methylbromides, methylnitrates, methylsulphates, nitrates, oleates, oxalates, palmitates, pantothenates, phosphates, diphosphates, polygalacturonates,
  • Hydrates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with water, such as for example hemi-, mono-, or dihydrates.
  • Solvates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with solvents.
  • the present invention includes both the individual enantiomers or diastereomers and the corresponding racemates or diastereomeric mixtures of the compounds according to the invention and their respective salts.
  • all possible tautomeric forms of the compounds described above are included according to the present invention.
  • the diastereomeric mixtures can be separated into the individual isomers by chromatographic processes.
  • the racemates can be resolved into the respective enantiomers either by chromatographic processes on chiral phases or by resolution.
  • CH shall also stand for a ring carbon atom, which is substituted with a substituent R 3 or R 7 .
  • A* symbol next to a bond denotes the point of attachment in the molecule.
  • the present invention relates to compounds according to general formula (I), wherein A is phenyl or pyridyl.
  • the present invention relates to compounds according to general formula (I), wherein R 1 is hydrogen.
  • the present invention relates to compounds according to general formula (I), wherein R 2 is cyano, especially wherein A is phenyl or pyridyl and R 2 is cyano located in para-position relative to the central dihydropyrimidinone ring.
  • the present invention relates to compounds according to general formula (I), wherein R 3 is hydrogen.
  • the present invention relates to compounds according to general formula (I), wherein R 5 is methyl.
  • the present invention relates to compounds according to general formula (I), wherein R 7 is trifluoromethyl or nitro, especially wherein R 7 is trifluoromethyl located in meta-position relative to the central dihydropyrimidinone ring.
  • the present invention relates to compounds of general formula (IA) wherein
  • the present invention relates to a process for synthesizing the compounds of general formula (I) or (IA), respectively.
  • the compounds of general formula (I) or (IA), respectively, can be synthesized by condensing compounds of general formula (II) wherein A, R 1 and R 2 have the meaning indicated above, with compounds of general formula (III) wherein R 4 and R 5 have the meaning indicated above, and compounds of general formula (IV) wherein R 3 , R 7 , and Y 1 to Y 5 have the meaning indicated above, in the presence of an acid or acid anhydride either in a three-component / one-step reaction or sequentially to give compounds of general formula (IB) wherein A, R 1 to R 5 , R 7 , and Y 1 to Y 5 have the meaning indicated above, optionally followed, in case R 6 does not represent hydrogen, by reaction of the compounds of general formula (IB) with compounds of general formula (V) R 6 *-X (V), wherein
  • Suitable solvents for the process (II) + (III) + (IV) ⁇ (IB) are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, diisopropyl ether, methyl t-butyl ether, 1,2-dimethoxyethane, dioxan or tetrahydrofuran, ethyl acetate, acetone, acetonitrile, dimethylsulfoxide, dimethylformamide, or alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or t-butanol, or hydrocarbons such as pentane, hexane, cyclohexane, benzene, toluene or xylene, or halogeno-hydrocarbons such as dichloromethane, dichloroethane, trichloromethane or chlorobenzene.
  • Suitable acids for the process (II) + (III) + (IV) ⁇ (IB) are generally inorganic or organic acids or acid anhydrides. These preferably include carboxylic acids, such as, for example, acetic acid or trifluoroacetic acid, sulfonic acids, such as, for example, methanesulfonic acid or p-toluenesulfonic acid, hydrochloric acid, phosphoric or phosphonic acids or anhydrides, such as polyphosphoric acid or propanephosphonic acid anhydride. Preference is given to polyphosphoric acid ethyl ester. The acid is employed in an amount from 0.25 mol to 100 mol, relative to 1 mol of the compound of the general formula (III).
  • the process is in general carried out in a temperature range from +20°C to +150°C, preferably from +60°C to +100°C.
  • the process is generally carried out at normal pressure. However, it is also possible to carry it out at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).
  • Suitable solvents for the process (IB) + (V) ⁇ (I) are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, diisopropyl ether, 1,2-dimethoxyethane, dioxan or tetrahydrofuran, ethyl acetate, acetone, acetonitrile, dimethylsulfoxide, dimethylformamide, or hydrocarbons such as pentane, hexane, cyclohexane, benzene, toluene or xylene, or halogeno-hydrocarbons such as dichloromethane, dichloroethane, trichloromethane or chlorobenzene. It is also possible to use mixtures of the above-mentioned solvents. Preferred for the process is tetrahydrofuran or dimethylformamide.
  • Suitable bases for the process (IB) + (V) ⁇ (I) are generally inorganic or organic bases. These preferably include alkali carbonates such as sodium or potassium carbonate or hydrogencarbonate, cyclic amines such as, for example, N -methylmorpholine, N -methylpiperidine, pyridine or 4- N,N- dimethylaminopyridine, or (C 1 -C 4 )-trialkylamines such as, for example, triethylamine or diisopropylethylamine, or alkali hydrides such as sodium or potassium hydride. Preference is given to potassium carbonate or sodium hydride.
  • the base is employed in an amount from 0.1 mol to 10 mol, preferably from 1 mol to 3 mol, relative to 1 mol of the compound of general formula (IV).
  • the process is in general carried out in a temperature range from 0°C to +150°C, preferably from +20°C to +80°C, especially at room temperature.
  • the compounds of the present invention can also be prepared, if appropriate, by functional group transformations of individual substituents, especially those listed under R 4 and R 6 , of the compounds of general formula (I) obtained by the process described above. These transformations are carried out using standard synthetic methods, e.g. by esterification, ester cleavage / hydrolysis, amide formation, catalytic hydrogenation, alkylation and/or aryl coupling reactions.
  • the compounds according to the invention exhibit an unforeseeable, useful pharmacological and pharmacokinetic activity spectrum. They are therefore suitable for use as medicaments for the treatment and/or prophylaxis of disorders in humans and animals.
  • the compounds of the present invention show human neutrophil elastase (HNE) inhibitory activity and are therefore suitable for the preparation of medicaments for the treatment of diseases associated with HNE activity. They may thus provide an effective treatment of acute and chronic inflammatory processes, such as rheumatoid arthritis, atherosclerosis, and especially of acute and chronic pulmonary diseases, such as lung fibrosis, cystic fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), in particular pulmonary emphysema, including smoking-induced emphysema, and chronic obstructive pulmonary diseases (COPD), chronic bronchitis and bronchiectasis.
  • HNE human neutrophil elastase
  • the compounds of the present invention may further provide an effective treatment for cardiovascular ischaemic diseases such as acute coronary syndrome, acute myocardial infarction, unstable and stable angina pectoris, coronary artery bypass grafts (CABG) and heart failure development, for atherosclerosis, mitral valvular disease, atrial septal defects, percutaneous transluminal coronary angioplasty (PTCA), inflammation after open heart surgery and for pulmonary hypertension.
  • cardiovascular ischaemic diseases such as acute coronary syndrome, acute myocardial infarction, unstable and stable angina pectoris, coronary artery bypass grafts (CABG) and heart failure development, for atherosclerosis, mitral valvular disease, atrial septal defects, percutaneous transluminal coronary angioplasty (PTCA), inflammation after open heart surgery and for pulmonary hypertension.
  • rheumatoid arthritis acute inflammatory arthritis, cancer, acute pancreatitis, ulcerative colitis, periodontal disease, Chury-Strauss syndrome, acute and chronic atopic dermatitis, psoriasis, systemic lupus erythematosus, bullous pemphigus, sepsis, alcoholic hepatitis, liver fibrosis, Behcet's disease, allergic fungal sinusitis, allergic sinusitis, Crohn's disease, Kawasaki disease, glomerulonephritis, acute pyelonephritis, colorectal diseases, chronic suppurative otitis media, chronic venous leg ulcers, inflammatory bowel disease, bacterial and viral infections, brain trauma, stroke and other conditions in which neutrophil participation is involved.
  • the present invention further provides medicaments containing at least one compound according to the invention, preferably together with one or more pharmacologically safe excipient or carrier substances, and also their use for the above-mentioned purposes.
  • the active component can act systemically and/or locally.
  • it can be applied in a suitable manner, for example orally, parenterally, pulmonally, nasally, sublingually, lingually, buccally, rectally, transdermally, conjunctivally, otically or as an implant.
  • the active component can be administered in suitable application forms.
  • Useful oral application forms include application forms which release the active component rapidly and/or in modified form, such as for example tablets (non-coated and coated tablets, for example with an enteric coating), capsules, sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, solutions and aerosols.
  • Parenteral application can be carried out with avoidance of an absorption step (intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or with inclusion of an absorption (intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally).
  • Useful parenteral application forms include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
  • Forms suitable for other application routes include for example inhalatory pharmaceutical forms (including powder inhalers, nebulizers), nasal drops/solutions, sprays; tablets or capsules to be administered lingually, sublingually or buccally, suppositories, ear and eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, milk, pastes, dusting powders or implants.
  • inhalatory pharmaceutical forms including powder inhalers, nebulizers
  • nasal drops/solutions, sprays including lingually, sublingually or buccally, suppositories, ear and eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, milk, pastes, dusting powders or implants.
  • the active components can be converted into the recited application forms in a manner known per se. This is carried out using inert non-toxic, pharmaceutically suitable excipients.
  • inert non-toxic, pharmaceutically suitable excipients include inter alia carriers (for example microcrystalline cellulose), solvents (for example liquid polyethylene glycols), emulsifiers (for example sodium dodecyl sulphate), dispersing agents (for example polyvinylpyrrolidone), synthetic and natural biopolymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), colorants (for example inorganic pigments such as iron oxides) or taste and/or odor corrigents.
  • carriers for example microcrystalline cellulose
  • solvents for example liquid polyethylene glycols
  • emulsifiers for example sodium dodecyl sulphate
  • dispersing agents for example polyvinylpyrrolidone
  • synthetic and natural biopolymers for example albumin
  • stabilizers for example antioxidant
  • oral administration in the case of oral administration, it is recommendable to administer doses of from 0.001 to 50 mg/kg, preferably of 0.01 mg/kg to 20 mg/kg.
  • parenteral administration such as, for example, intravenously or via mucous membranes nasally, buccally or inhalationally, it is recommendable to use doses of 0.001 mg/kg to 0.5 mg/kg.
  • HNE human neutrophil elastase
  • assay buffer 0.1 M HEPES-NaOH buffer pH 7.4, 0.5 M NaCl, 0.1 % (w/v) bovine serum albumin; suitable concentration (see below) of HNE (18 U/mg lyophil., #20927.01, SERVA Electrophoresis GmbH, Heidelberg, Germany) in assay buffer; suitable concentration (see below) of substrate in assay buffer; suitable concentration of test compounds diluted with assay buffer from a 10 mM stock solution in DMSO.
  • the elastase substrate MeOSuc-Ala-Ala-Pro-Val-AMC (#324740, Calbiochem-Novabiochem Corporation, Merck KGaA, Darmstadt, Germany) is used.
  • the test solution is prepared by mixing 10 ⁇ l of test compound dilution, 20 ⁇ l of HNE enzyme dilution (final concentration 8 - 0.4 ⁇ U/ml, routinely 2.1 ⁇ U/ml) and 20 ⁇ l of substrate dilution (final concentration 1 mM - 1 ⁇ M, routinely 20 ⁇ M), respectively.
  • the solution is incubated for 0 - 2 hrs at 37°C (routinely one hour).
  • the fluorescence of the liberated AMC due to the enzymatic reaction is measured at 37°C (TECAN spectra fluor plus plate reader).
  • the rate of increase of the fluorescence (ex. 395 nm, em. 460 nm) is proportional to elastase activity.
  • IC 50 values are determined by RFU-versus-[I] plots.
  • K m and K m(app.) values are determined by Lineweaver-Burk plots and converted to K i values by Dixon plots.
  • the preparation examples have IC 50 values within the range of 5 nM - 5 ⁇ M in this assay. Representative data are given in Table 1: Table 1 Example No. IC 50 [nM] 1 20 5 5 6 200 14 1000 21 130 43 23 45 20 69 50 73 1000 78 50
  • the elastase substrate elastin-fluorescein (#100620, ICN Biomedicals GmbH, Eschwege, Germany) is used.
  • the test solution is prepared by mixing 3 ⁇ l of test compound dilution, 77 ⁇ l of HNE enzyme dilution (final concentration 0.22 U/ml - 2.2 mU/ml, routinely 21.7 ⁇ U/ml) and 80 ⁇ l substrate suspension (final concentration 2 mg/ml).
  • the suspension is incubated for 0 - 16 hrs at 37°C (routinely four hours) under slightly shaking conditions.
  • 160 ⁇ l of 0.1 M acetic acid are added to the test solution (final concentration 50 mM).
  • the polymeric elastin-fluorescein is pulled down by centrifugation (Eppendorf 5804 centrifuge, 3.000 rpm, 10 min). The supernatant is transferred into a new MTP and the fluorescence of the liberated peptide fluorescein due to the enzymatic reaction is measured (BMG Fluostar plate reader). The rate of fluorescence (ex. 490 nm, em. 520 nm) is proportional to elastase activity. IC 50 values are determined by RFU-versus-[I] plots.
  • This assay is used to determine the elastolytic potential of human polymorphonuclear cells (PMNs) and assess the proportion of degradation due to neutrophil elastase [cf. Z.W. She et al., Am. J. Respir. Cell. Mol. Biol. 9, 386-392 (1993 )].
  • Tritiated elastin, in suspension, is coated on to a 96 well plate at 10 ⁇ g per well.
  • Test and reference [ZD-0892 ( J. Med. Chem. 40, 1876-1885, 3173-3181 (1997 ), WO 95/21855 ) and ⁇ 1 protease inhibitor ( ⁇ 1PI)] compounds are added to the wells at the appropriate concentrations.
  • Human PMNs are separated from peripheral venous blood of healthy donors and resuspended in culture media.
  • the neutrophils are added to the coated wells at concentrations ranging between 1 x 10 6 to 1 x 10 5 cells per well.
  • Porcine pancreatic elastase (1.3 ⁇ M) is used as a positive control for the assay, and ⁇ 1PI (1.2 ⁇ M) is used as the positive inhibitor of neutrophil elastase.
  • the cellular control is PMNs without compound at each appropriate cell density.
  • the cells plus compounds are incubated in a humidified incubator at 37°C for 4 hours.
  • the plates are centrifuged to allow the harvest of cell supernatant only.
  • the supernatant is transferred in 75 ⁇ l volumes to corresponding wells of a 96 well LumaplateTM (solid scintillant containing plates). The plates are dried until no liquid is visible in the wells and read in a beta counter for 3 minutes per well.
  • Elastolysis of the 3 H-elastin results in an increase in counts in the supernatant.
  • An inhibition of this elastolysis shows a decrease, from the cellular control, of tritium in the supernatant.
  • ZD-0892 is a selective inhibitor of PMN elastase along with the data from ⁇ 1PI inhibition, these results indicate that the majority of elastin degradation by PMNs is due to the release of neutrophil elastase, and not to another elastolytic enzyme such as matrix metalloproteases (MMPs).
  • MMPs matrix metalloproteases
  • Measurement of the inhibition of elastase bound to neutrophil membranes is performed using a human neutrophil assay. Neutrophils are stimulated with LPS at 37°C for 35 min and then spun at 1600 rpm. Subsequently, the membrane bound elastase is fixed to the neutrophils with 3% paraformaldehyde and 0.25% glutaraldehyde for 3 min at 4°C. The neutrophils are then spun, and vehicle and the compound under evaluation are added, followed by addition of the substrate MeOSuc-Ala-Ala-Pro-Val-AMC (#324740, Calbiochem-Novabiochem Corporation, Merck KGaA, Darmstadt, Germany) at 200 ⁇ M.
  • IC 50 values are determined by interpolation from plots of relative fluorescence vs. inhibitor concentration.
  • HNE human neutrophil elastase
  • Rats are anaesthetised with Hypnorm/Hypnovel/water and instilled with HNE or saline delivered by microsprayer into the lungs.
  • Test compounds are administered by intravenous injection, by oral gavage or by inhalation at set times prior to the administration of HNE.
  • Sixty minutes after the administration of elastase animals are killed by an anaesthetic overdose (sodium pentobarbitone) and the lungs lavaged with 2 ml heparinised phosphate buffered saline (PBS).
  • Bronchoalveolar lavage (BAL) volume is recorded and the samples kept on ice. Each BAL sample is centrifuged at 900 r.p.m.
  • the absorbance of the well contents is measured at 415 nm using a spectrophotometer.
  • a standard curve is constructed by measuring the OD at 415 nm of different concentrations of blood in 0.1% CTAB/PBS. Blood content values are calculated by comparison to the standard curve (included in each plate) and normalised for the volume of BAL fluid retrieved.
  • the compounds of this invention are evaluated intravenously, orally or by inhalation for their inhibitory activity in this model of HNE-induced haemorrhage in the rat.
  • Elastase inhibitors are tested in a rat thread infarct model.
  • Male Wistar rats (weighing >300 g) receive 10 mg/kg aspirin 30 min prior to surgery. They are anaesthetized by isofluran and ventilated (120-130 strokes/min, 200-250 ⁇ l stroke volume; MiniVent Type 845, Hugo Sachs Elektronik, Germany) during the whole surgery.
  • the pericardium is opened and the heart briefly exteriorized.
  • a thread is turned around the left coronary artery (LAD) without occluding the artery. The thread is passed under the skin to the neck of the animal. The thorax is closed and the animal is allowed to recover for 4 days.
  • LAD left coronary artery
  • rats are anaesthetized with ether for 3 min, and the thread is tied and the LAD occluded under ECG control.
  • Test compounds are administered before or after LAD occlusion per os, intraperitoneally or intravenously (bolus or permanent infusion). After 1 hr occlusion, the thread is reopened to allow reperfusion.
  • Hearts are excised, and infarct sizes are determined 48 hours later by staining of the re-occluded hearts with Evans blue, followed by TTC (triphenyltetrazolium chloride) staining of 2 mm heart sections.
  • Normoxic not occluded tissue areas stain blue, ischemic (occluded but surviving tissue) areas stain red and necrotic (occluded dead tissue) areas remain white. Each tissue section is scanned and infarct sizes are determined by computer planimetry.
  • Instrument MS Micromass ZQ
  • Instrument HPLC Waters Alliance 2795
  • column Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm
  • eluent A 1 1 water + 0.5 ml 50% formic acid
  • eluent B 1 1 acetonitrile + 0.5 ml 50% formic acid
  • gradient 0.0 min 90% A ⁇ 2.5 min 30% A ⁇ 3.0 min 5%
  • ⁇ 4.5 min 5% A flow: 0.0 min 1 ml/min ⁇ 2.5 min/3.0 min/4.5 min 2 ml/min
  • oven 50°C
  • UV detection 210 nm.
  • Instrument MS Micromass ZQ
  • Instrument HPLC HP 1100 Series with DAD detection
  • column Phenomenex Synergi 2 ⁇ Hydro-RP Mercury 20 mm x 4 mm
  • eluent A 1 1 water + 0.5 ml 50% formic acid
  • eluent B 1 1 acetonitrile + 0.5 ml 50% formic acid
  • gradient 0.0 min 90% A ⁇ 2.5 min 30% A ⁇ 3.0 min 5% A ⁇ 4.5 min 5% A
  • flow 0.0 min 1 ml/min ⁇ 2.5 min/3.0 min/4.5 min 2 ml/min
  • oven 50°C
  • UV detection 210 nm.
  • Example 2A The enantiomers of Example 2A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N -methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate ⁇ methanol ⁇ ethyl acetate; flow 50 ml/min; temperature 24°C; detection 280 nm].
  • a chiral phase based on monomer N -methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate ⁇ methanol ⁇ ethyl acetate; flow 50 ml/min; temperature 24°C; detection 280 nm].
  • Example 1A 3 g (7 mmol) of Example 1A are dissolved in a mixture of 50 ml water and 100 ml 5% potassium hydroxide in ethanol. The reaction mixture is stirred at room temperature for 18 hours. The solvent is removed in vacuo and the residue is purified by column chromatography on silica with dichloromethane/methanol as eluent.
  • Example 5A The enantiomers of Example 5A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N -methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate ⁇ methanol ⁇ ethyl acetate; flow 25 ml/min; temperature 23°C; detection 254 nm].
  • a chiral phase based on monomer N -methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate ⁇ methanol ⁇ ethyl acetate; flow 25 ml/min; temperature 23°C; detection 254 nm].
  • Example 6A Under argon, 1560 mg (3.89 mmol) of Example 6A are added to 19.6 ml dimethylformamide. After addition of 1.095 ml (7.86 mmol) triethylamine and 1.11 ml (15.7 mmol) 2-bromoethanol, the reaction mixture is stirred at ca. 70°C for 8 hours. After cooling to room temperature, the reaction mixture is concentrated in vacuo. The residue is taken up in ethyl acetate and washed with water. After drying with magnesium sulfate, the organic phase is evaporated in vacuo.
  • Example 8A The title compound is prepared according to the procedure described in Example 8A and is isolated as the enol ether.
  • Example 2A 1000 mg (2.27 mmol) of Example 2A are dissolved in 10 ml dimethylformamide, 344 mg (2.49 mmol) potassium carbonate and 486 mg (2.49 mmol) tert. -butyl bromoacetate are added, and the suspension is stirred at room temperature overnight. The mixture is partitioned between ethyl acetate and aqueous potassium dihydrogenphosphate/disodium hydrogenphosphate buffer (pH 7). The combined organic extracts are washed with water and aqueous sodium chloride solution, dried over magnesium sulfate, and evaporated in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 3:1).
  • Example 14A 372 mg (0.72 mmol) of Example 14A are dissolved in 5 ml dimethylformamide, 351 mg (2.17 mmol) 1,1'-carbonyldiimidazole are added, and the mixture is stirred at room temperature overnight. The mixture is partitioned between water and ethyl acetate, the combined organic extracts are washed with aqueous sodium hydrogencarbonate solution, water and aqueous sodium chloride solution, dried over magnesium sulfate, filtered and evaporated to dryness in vacuo.
  • Example 5A 500 mg (1.25 mmol) of Example 5A, 310 mg (1.62 mmol) 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimid-hydrochloride and 202 mg (1.49 mmol) 1-hydroxybenzotriazole are dissolved in 2 ml dimethylformamide and stirred at room temperature overnight. The reaction mixture is partitioned between ethyl acetate and water, the organic phase is washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated to dryness in vacuo. The crude product is used directly for further reactions.
  • Example 259 mg (0.62 mmol) tribenzyl methanetricarboxylate and 203 mg (0.77 mmol) triphenylphosphine are dissolved in 3 ml tetrahydrofuran under an argon atmosphere.
  • the solution is cooled to 0°C, and 156 mg (0.77 mmol) diisopropyl azodicarboxylate are added slowly.
  • the mixture is warmed to room temperature overnight, evaporated to dryness and purified directly by vacuum flash chromatography on silica (eluent: petrol ether/ethyl acetate 2:1 ⁇ 1:1) and thereafter by RP-HPLC (eluent: acetonitrile/water gradient).
  • Example 4A The enantiomers of Example 4A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N -methacryloyl-L-leucine-1-menthylamide, cf . EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate ⁇ methanol ⁇ ethyl acetate; flow 25 ml/min; temperature 23°C; detection 254 nm].
  • Example 4 1.0 g (2.58 mmol) of Example 4, 1.3 g (3.10 mmol) tribenzyl methanetricarboxylate and 1.02 g (3.87 mmol) triphenylphosphine are dissolved in 15 ml tetrahydrofuran under an argon atmosphere. The solution is cooled to 0°C, and 0.67 g (3.87 mmol) diisopropyl azodicarboxylate are added slowly. The mixture is warmed to room temperature overnight, evaporated to dryness and purified directly by vacuum flash chromatography on silica (eluent: cyclohexane/ethyl acetate 2:1 ⁇ 1:1).
  • the ether layer is washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo.
  • the crude product is chromatographed over silica gel 60 with dichloromethane as eluent. The compound is isolated as its enol ether.
  • Example 1A 2.05 g (4.77 mmol) of Example 1A are dissolved in 40 ml tetrahydrofuran. At 0°C, 9.55 ml (9.55 mmol) of 1 M lithium aluminiumhydride in tetrahydrofuran are added dropwise. The solution is stirred at 0°C for two hours and then quenched with methanol. The solvent is removed in vacuo and the residue is purified by column chromatography on silica with dichloromethane/methanol mixtures as eluent.
  • Example 4A 200 mg (0.5 mmol) of Example 4A and 49 mg (0.6 mmol) sodium acetate are dissolved in 5 ml ethanol. 47 mg (1.25 mmol) sodium borohydride are added. The solution is stirred at room temperature for 16 hours, then water is added. The product precipitates as mixture of diastereomers (94 mg). The diastereomers are separated by preparative HPLC.
  • Example 3A 3.00 g (6.80 mmol) of Example 3A are dissolved in 20 ml dry tetrahydrofuran, 6.80 ml (6.80 mmol) of 1 M lithium aluminiumhydride in tetrahydrofuran are added slowly, and stirring is continued for 30 minutes at 0°C. Saturated ammonium chloride solution is added cautiously to hydrolyze excess of lithium aluminiumhydride, followed by 50 ml ethyl acetate and dropwise addition of water to precipitate inorganic salts. The organic phase is decanted, washed with water, dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography over silica gel (eluent: dichloromethane/methanol 100:0 ⁇ 95:5).
  • Example 7A 80 mg (0.18 mmol) of Example 7A are dissolved in 4 ml tetrahydrofuran, and 36 mg (0.9 mmol) sodium hydride (60% suspension in mineral oil) are added. After stirring for one hour at room temperature, 50 mg (0.36 mmol) bromoacetic acid are added. After stirring at room temperature for four hours, the mixture is quenched with methanol, the solvent is removed in vacuo and the residue is purified by preparative HPLC.
  • Example 5A 100 mg (0.25 mmol) of Example 5A are dissolved in 2 ml tetrahydrofuran, and 3 mg (0.02 mmol) 4- N,N -dimethylaminopyridine, 39 mg (0.3 mmol) N,N -diisopropylethylamine and 156 mg (0.3 mmol) benzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluorophosphate are added. The reaction mixture is stirred at room temperature for 15 minutes, then 29 mg (0.5 mmol) cyclopropylamine are added. The reaction mixture is stirred at room temperature for 72 hours. The mixture is evaporated to dryness in vacuo and the crude product is purified by preparative HPLC.
  • Example 5A Example No. Structure Starting materials Yield [%] R t [min] (method) Mass [M+H] + 7
  • Example 22 The enantiomers of Example 22 are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on poly(N-methacryloyl-L-leucine-dicyclopropylmethylamide); column: 250 mm x 20 mm; gradient: 0-6 minutes ethyl acetate, 6-8 minutes methanol, 8-10 minutes ethyl acetate; flow: 25 ml/min; detection: UV 254 nm].
  • Example 22 The title compound is prepared from Example 22 according to the procedure described for Example 26.
  • Example 21 The title compound is prepared from Example 21 according to the procedure described for Example 26.
  • Example 25 The title compound is prepared from Example 25 according to the procedure described for Example 26.
  • Example 27 The title compound is prepared from Example 27 according to the procedure described for Example 30.
  • Example 28 The title compound is prepared from Example 28 according to the procedure described for Example 30.
  • Example 24 The title compound is prepared from Example 24 according to the procedure described for Example 26.
  • the title compound is prepared from Example 33 according to the procedure described for Example 30.
  • Example 35 The title compound is prepared from Example 35 according to the procedure described for Example 30, with the exception that the reaction time is 30 minutes, and the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90:10).
  • the title compound is prepared from Example 21 according to the procedure described for Example 35.
  • Example 38 The title compound is prepared from Example 38 according to the procedure described for Example 30, with the exception that the reaction time is 30 minutes, and the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90:10).
  • the suspension is stirred at room temperature overnight (16 h), then additional methyl 5-(chloromethyl)-2-furoate (6.1 mg, 0.35 mmol) and potassium carbonate (49 mg, 0.35 mmol) are added, and the suspension is stirred an additional 72 hours.
  • the reaction mixture is diluted with methanol (5 ml) and purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 10:90 ⁇ 90:10).
  • the title compound is isolated as a brownish amorphous solid.
  • reaction mixture is stirred at room temperature overnight, then an additional equivalent of potassium carbonate (0.35 mmol) and methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate (0.35 mmol) are added, and the solution is stirred an additional 72 hours.
  • the reaction mixture is quenched with water (20 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90:10).
  • the crude product is extracted with dichloromethane (100 ml), washed with 2 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, filtered and concentrated.
  • the residue is purified by flash chromatography with silica gel 60 (50 g) and 2:1 cyclohexane/ethyl acetate as eluent.
  • Example 21 The title compound is prepared from Example 21 according to the procedure described for Example 42, with the exception that only 1.5 equivalents of methyl 5-(chloromethyl)-2-furoate and 2 equivalents of potassium carbonate are used.
  • the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 30:70 ⁇ 90:10).
  • Example 21 The title compound is prepared from Example 21 according to the procedure described for Example 43, with the exception that only 2 equivalents of potassium carbonate and 1.5 equivalents of methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate are used.
  • the reaction time is 72 hours.
  • reaction solution is stirred overnight (16 h), then allowed to stand for 48 h.
  • the solution is acidified with 1 N hydrochloric acid (500 ⁇ l). After 5 minutes stirring, a precipitate is obtained.
  • Methanol (3 ml) is added, and the crude reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90:10).
  • the title compound is isolated as a brownish solid.
  • Example 32 The title compound is prepared from Example 32 according to the procedure described for Example 44, with the exception that the title compound is purified by HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90: 10).
  • Example 32 The title compound is prepared from Example 32 according to the procedure described for Example 45, with the exception that the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 ⁇ 90:10).
  • the pH of the solution is adjusted to less than pH 7 with 1 N hydrochloric acid (500 ⁇ l). After 5 minutes stirring, a precipitate is obtained. Methanol (3 ml) is added, and the crude reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 30:70 ⁇ 90:10). The title compound is isolated as a colourless solid.
  • Example 46 The title compound is prepared from Example 46 according to the procedure described for Example 48, with the exception that the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 ⁇ 90:10).
  • Example 47 The title compound is prepared from Example 47 according to the procedure described for Example 51, with the exception that the title compound is purified by preparative HPLC (RP 18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 ⁇ 90:10).
  • the product is extracted with methyl tert .-butyl ether (300 ml), washed with aq. saturated sodium bicarbonate solution (200 ml), dried with anhydrous magnesium sulfate, filtered and concentrated. The residue is chromatographed with silica gel 60 using cyclohexane / ethyl acetate as eluent.
  • the title compound is prepared from Example 54 according to the procedure described for Example 26.
  • the title compound is prepared from Example 55 according to the procedure described for Example 30.
  • the mixture is partitioned between ethyl acetate and 2 N hydrochloric acid, the organic phase is sequentially washed with water and saturated sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo.
  • the crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 2:1 ⁇ 0:1) and thereafter by RP-HPLC with a water/acetonitrile gradient.
  • Example 59 100 mg (0.16 mmol) of Example 59 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature for 1 hour. Volatiles are evaporated in vacuo and the crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 1:1).
  • Example 6A 200 mg (0.50 mmol) of Example 6A are dissolved in 2.0 ml dimethylformamide. 456 mg (1.99 mmol) benzyl bromoacetate and 100 mg (1.00 mmol) triethylamine are added, and the mixture is stirred at room temperature for 2 hours. The reaction mixture is partitioned between ethyl acetate and 2 N hydrochloric acid, the organic layer is sequentially washed with water and saturated sodium chloride solution, dried over magnesium sulfate and evaporated to dryness in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 1:1 ⁇ 0:1).
  • Example 57 60 5.91(1) 770
  • Example 58 62 5.58(1) 678
  • Example 15A 70 mg (0.12 mmol) of Example 15A and 521 mg (3.23 mmol) tert .-butyl- N -hydroxyethyl carbamate are reacted at 100°C for 150 minutes.
  • the reaction mixture is diluted with acetonitrile and purified using preparative RP-HPLC (eluent: acetonitrile/water gradient).
  • Example 64 The title compound is synthesized in analogy to Example 64 from Example 15A using N-(2-hydroxyethyl)-2-pyrrolidone instead of tert.-butyl-N-hydroxyethyl carbamate.
  • Example 64 The title compound is synthesized in analogy to Example 64 from Example 15A using benzyl hydroxyacetate instead of tert .-butyl- N -hydroxyethyl carbamate.
  • Example 65 34.9 mg of Example 65 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Example 14A 100 mg (0.19 mmol) of Example 14A, 36.9 mg (0.39 mmol) methanesulfonamide, 44.0 mg (0.21 mmol) dicyclohexylcarbodiimide and 26.1 mg (0.21 mmol) 4- N , N -dimethylaminopyridine are dissolved in dry dichloromethane (2 ml) and reacted overnight. The reaction mixture is filtered, the filtrate is sequentially washed with 2 M hydrochloric acid, water and saturated ammonium chloride solution, and the organic phase is dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate/acetic acid 50:50:1).
  • Example 14A 2,2,2-trifluoro-ethanesulfon-amide 71 5.12(1) 661 70
  • Example 68 45.6 mg (0.08 mmol) of Example 68 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature for 1 hour. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC with a water/acetonitrile gradient.
  • Example 1 50 mg (0.13 mmol) of Example 1 are dissolved in 1 ml tetrahydrofuran, 10.8 mg (0.27 mmol) sodium hydride are added, and the mixture is stirred for 15 minutes at room temperature. 27 mg (0.14 mmol) tert .-butyl bromoacetate is added, and the mixture is stirred at room temperature for 1 hour. Saturated aq. ammonium chloride solution is added, and the reaction mixture is diluted with ethyl acetate. The organic phase is washed with water, dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography over silica gel (eluent: cyclohexane/ethyl acetate).
  • Example 17A und 5.00 mg palladium on charcoal (10%) are suspended in 5 ml ethanol and hydrogenated under 1 atm hydrogen at room temperature for 12 minutes. The reaction mixture is filtered over celite and the residue is washed with ethanol. The filtrate is evaporated to dryness in vacuo and the remainder is heated without solvent at 130°C under an argon atmosphere for 20 minutes. The crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Example 19A 200 mg (0.25 mmol) of Example 19A und 5.0 mg palladium on charcoal (10%) are suspended in 10 ml ethanol and hydrogenated under 1 atm hydrogen at room temperature for 15 minutes. The reaction mixture is filtered over celite and the residue is washed with ethanol. The filtrate is evaporated to dryness in vacuo and the crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Example 79 40 mg (0.08 mmol) of Example 79 are heated without solvent at 130°C under an argon atmosphere for 20 minutes. The crude product is purified by column chromatography (silica, eluent: dichloromethane/methanol 20:1).
  • Example 18A 300 mg (0.75 mmol) of Example 18A are dissolved in 5 ml tetrahydrofuran. At 0°C, 28.5 mg (0.75 mmol) lithium aluminium hydride (as 1 M solution in tetrahydrofuran) are added slowly. The dark-red solution is stirred at 0°C for 30 minutes, then water is added. The pH is adjusted to 3-4 with 1 N hydrochloric acid. The crude product is extracted with ethyl acetate and purified and separated by column chromatography (silica, eluent: dichloromethane/methanol 40:1).
  • Example 83 5.32 g (9.85 mmol) of Example 83 are dissolved in 150 ml tetrahydrofuran, and 0.98 g (24.61 mmol) sodium hydride (60% suspension in mineral oil) are added slowly. After stirring for one hour at room temperature, 2.88 g (14.77 mmol) tert.-butyl bromoacetate are added. After stirring at room temperature for one hour, the mixture is quenched with water, the solvent is removed in vacuo and the residue is purified by column chromatography (silica, eluent: cyclohexane/ethyl acetate 10:1, 5:1).
  • Example 84 100 mg (0.15 mmol) of Example 84 are dissolved in 10 ml dichloromethane and 0.25 ml trifluoroacetic acid, and the mixture is stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Example 84 100 mg (0.15 mmol) of Example 84 are dissolved in 5 ml N,N -dimethylformamide under an argon atmosphere, and 19 mg (0.15 mmol) phenylboronic acid, 100 mg (0.31 mmol) cesium carbonate and 5 mg dichloro[bis(triphenylphosphino)palladium are added. The reaction mixture is stirred at 120°C for 18 hours. The product is purified by RP-HPLC using a water/acetonitrile gradient.
  • Example 86 30 mg (0.05 mmol) of Example 86 are dissolved in 2 ml dichloromethane and 0.07 ml trifluoroacetic acid, and the mixture is stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Example 88 5.27 g (10.41 mmol) of Example 88 are dissolved in 150 ml tetrahydrofuran, and 1.04 g (26.02 mmol) sodium hydride (60% suspension in mineral oil) are added slowly. After stirring for one hour at room temperature, 3.04 g (15.61 mmol) tert.-butyl bromoacetate are added. After stirring at room temperature for one hour, the mixture is quenched with water, the solvent is removed in vacuo and the residue is purified by column chromatography (silica, eluent: cyclohexane/ethyl acetate 10:1, 5:1).
  • Example 89 und 5 mg palladium on charcoal (10%) are suspended in 20 ml tetrahydrofuran and hydrogenated under 1 atm hydrogen at room temperature for 18 hours.
  • the reaction mixture is filtered over celite, the filtrate is evaporated to dryness in vacuo and the crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Example 23 The title compound is prepared from Example 23 according to the procedure described for Example 26.
  • Example 91 The title compound is prepared from Example 91 according to the procedure described for Example 30.
  • Example 20A 120 mg, 0.64 mmol
  • N -[3-(trifluoromethyl)phenyl]urea 109 mg, 0.54 mmol
  • 4-cyanobenzaldehyde 84.5 mg, 0.64 mmol
  • methyl tert .-butyl ether 5 ml
  • 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (683 mg, 1 mmol).
  • the solution is refluxed overnight under argon, then cooled to room temperature, quenched with water (200 ml) and extracted with methyl tert.-butyl ether (3 x 100 ml).
  • the combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated.
  • the residue is purified by preparative HPLC.
  • Example 21 To a stirred solution of Example 21 (780 mg, 1.67 mmol) in THF (25 ml) is added sodium hydride (60% dispersion in mineral oil; 653 mg, 2.53 mmol). The mixture is stirred for 1 hour at room temperature, then 2-bromo- N , N -diethylethanamine (653 mg, 2.53 mmol) is added, and the solution is stirred overnight (16 h) at room temperature. The reaction mixture is quenched with methanol (10 ml), concentrated, and the crude product is purified by preparative HPLC.
  • Example 22 The title compound is prepared from Example 22 according to the procedure described for Example 94.
  • Example 93 The title compound is prepared from Example 93 according to the procedure described for Example 26.
  • Example 93 The title compound is prepared from Example 93 according to the procedure described for Example 26.
  • Example 95 The enantiomers of Example 95 are separated by preparative HPLC on a chiral phase [Daicel Chiralpak AD-H, 5 ⁇ m; 250 mm x 20 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 15 ml/min; temperature 25°C; detection 220 nm].
  • Example 94 The enantiomers of Example 94 are separated by preparative HPLC on a chiral phase [Daicel Chiralpak AD-H, 5 ⁇ m; 250 mm x 20 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 15 ml/min; temperature 25°C; detection 220 nm].
  • the compounds according to the invention can be converted into pharmaceutical preparations as follows:
  • Example 1 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of maize starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate.
  • the mixture of active component, lactose and starch is granulated with a 5% solution (m/m) of the PVP in water. After drying, the granules are mixed with magnesium stearate for 5 min. This mixture is moulded using a customary tablet press (tablet format, see above). The moulding force applied is typically 15 kN.
  • a single dose of 100 mg of the compound according to the invention is provided by 10 ml of oral suspension.
  • Rhodigel is suspended in ethanol and the active component is added to the suspension.
  • the water is added with stirring. Stirring is continued for about 6h until the swelling of the Rhodigel is complete.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to novel heterocyclic derivatives of the general formula (I), processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.

Description

  • The present invention relates to novel heterocyclic derivatives, processes for their preparation, and their use in medicaments, especially for the treatment of chronic obstructive pulmonary diseases, acute coronary syndrome, acute myocardial infarction and heart failure development.
  • The fibrous protein elastin, which comprises an appreciable percentage of all protein content in some tissues, such as the arteries, some ligaments, the lungs and the heart, can be hydrolysed or otherwise destroyed by a select group of enzymes classified as elastases. Human leukocyte elastase (HLE, EC 3.4.21.37), also known as human neutrophil elastase (HNE), is a glycosylated, strongly basic serine protease and is found in the azurophilic granules of human polymorphonuclear leukocytes (PMN). HNE is released from activated PMN and has been implicated causally in the pathogenesis of acute and chronic inflammatory diseases. HNE is capable of degrading a wide range of matrix proteins including elastin and collagen, and in addition to these actions on connective tissue HNE has a broad range of inflammatory actions including upregulation of IL-8 gene expression, oedema formation, mucus gland hyperplasia and mucus hypersecretion. It also acts as a mediator of tissue injury by hydrolysing collagen structures, e.g. in the heart after acute myocardial infarction or during the development of heart failure, thus damaging endothelial cells, promoting extravasation of neutrophils adhering to the endothelium and influencing the adhesion process itself.
  • Pulmonary diseases where HNE is believed to play a role include lung fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), pulmonary emphysema, including smoking-induced emphysema, chronic obstructive pulmonary diseases (COPD) and cystic fibrosis. In cardiovascular diseases, HNE is involved in the enhanced generation of ischaemic tissue injury followed by myocardial dysfunction after acute myocardial infarction and in the remodelling processes occurring during the development of heart failure. HNE has also been causally implicated in rheumatoid arthritis, atherosclerosis, brain trauma, cancer and related conditions in which neutrophil participation is involved.
  • Thus, inhibitors of HLE activity can be potentially useful in the treatment of a number of inflammatory diseases, especially of chronic obstructive pulmonary diseases [R.A. Stockley, Neutrophils and protease/antiprotease imbalance, Am. J. Respir. Crit. Care 160, S49-S52 (1999)]. Inhibitors of HLE activity can also be potentially useful in the treatment of acute myocardial syndrome, unstable angina pectoris, acute myocardial infarction and coronary artery bypass grafts (CABG) [C.P. Tiefenbacher et al., Inhibition of elastase improves myocardial function after repetitive ischaemia and myocardial infarction in the rat heart, Eur. J. Physiol. 433, S563-S570 (1997); Dinerman et al., Increased neutrophil elastase release in unstable angina pectoris and acute myocardial infarction, J. Am. Coll. Cardiol. 15, 1559-1563 (1990)], of the development of heart failure [S.J. Gilbert et al., Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy, Cardiov. Res. 34, S377-S383 (1997)] and of atherosclerosis [Dollery et al., Neutrophil elastase in human atherosclerotic plaque, Circulation 107, 2829-2836 (2003)].
  • The synthesis of 5-ethoxycarbonyl-1-phenyl-6-methyl-4-(3-nitrophenyl)-3,4-dihydropyrimidin-2(1H)-one is described in J. Heterocyclic Chem. 38, 1051 (2001). A pharmacological activity of this compound is not mentioned.
  • WO 03/053930 describes 1,4-bis(hetero)aryl-dihydropyridines useful as HNE inhibitors, particularly in the treatment of chronic obstructive pulmonary diseases.
  • The present invention relates to compounds of the general formula (I)
    Figure imgb0001
     wherein
    • A
    represents a phenyl or a pyridyl ring,
    R1 and R3
    each represent hydrogen,
    R2
    represents fluoro, chloro, bromo, nitro or cyano,
    R4
    represents
    • C1-C4-alkyl which can be substituted by up to two radicals independently selected from the group consisting of hydroxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl, -
    • C3-C6-cycloalkylcarbonyl which can be substituted by up to two radicals independently selected from the group consisting of C1-C4-alkyl, hydroxy, oxo, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    • benzoyl which is substituted by one, two or three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    • C)-C4-alkoxycarbonyl which is substituted by one or two radicals independently selected from the group consisting of benzyloxy, benzyloxycarbonyl, C1-C4-alkoxy, C1-C4-alkoxycarbonylamino, pyrrolidinyl, piperidinyl and morpholinyl, wherein C1-C4-alkoxy is further substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl, and wherein pyrrolidinyl, piperidinyl and morpholinyl is further substituted by hydroxy, oxo, C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    • furylcarbonyl, oxazolylcarbonyl, thiazolylcarbonyl or pyridylcarbonyl each of which is substituted by one or two radicals independently selected from the group consisting of hydroxy, amino, fluoro, chloro, bromo, C1-C4-alkoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl, and each of which can additionally be substituted by C1-C4-alkyl,
    • mono- or di-C1-C4-alkylaminocarbonyl wherein the alkyl moiety or at least one alkyl moiety, respectively, is substituted by phenyl which for its part can be further substituted by up to three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    • piperidinylcarbonyl, piperazinylcarbonyl or morpholinylcarbonyl each of which is substituted by one or two radicals independently selected from the group consisting of C1-C4-alkyl, hydroxy, oxo, C1-C4-alkoxy, C1-C4-alkoxycarbonyl, benzyloxycarbonyl, hydroxycarbonyl, piperidinyl, morpholinyl, pyridyl and phenyl, wherein C1-C4-alkyl is further substituted by hydroxy, C1-C4-alkoxy, C1-C4-alkoxycarbonyl or hydroxycarbonyl, and wherein phenyl can be further substituted by up to three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
      or
    • a group of the formula -C(=O)-NH-SO2-Rb wherein Rb represents C1-C4-alkyl which can be substituted by trifluoromethyl, or Rb represents phenyl which can be substituted by C1-C4-alkyl, fluoro, chloro, bromo, cyano, nitro or trifluoromethyl,
    R5
    represents methyl,
    R6
    represents hydrogen, C1-C4-alkyl, mono- or di-C1-C4-alkylaminocarbonyl, C1-C4-alkylcarbonyl or C1-C4-alkoxycarbonyl, wherein C1-C4-alkyl and C1-C4-alkoxycarbonyl can be substituted with a radical selected from the group consisting of hydroxy, C1-C4-alkoxy, C1-C4-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- and di-C1-C4-alkylaminocarbonyl, amino, mono- and di-C1-C4-alkylamino, or
    R6
    represents a moiety of the formula
    Figure imgb0002
     wherein
    Rd is selected from the group consisting of hydrogen and methyl, or
    R6
    represents a group of the formula -T-U wherein
    T represents a -CH2- group
    and
    U represents
    • phenyl, furyl or oxazolyl each of which is substituted by one or two radicals independently selected from the group consisting of fluoro, chloro, bromo, C1-C4-alkyl and a group of the formula -V-W wherein V represents a bond, a -CH2- group or a -CH=CH- group, and W represents C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    • a group of the formula -C(=O)-NH-SO2-Rf wherein Rf represents C1-C4-alkyl which can be substituted by trifluoromethyl, or Rf represents phenyl which can be substituted by C1-C4-alkyl, fluoro, chloro, bromo, cyano, nitro or trifluoromethyl,
      or
    • a group of the formula -C(=O)-NHRh wherein Rh represents phenyl which can be substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    or
    R6 represents
    • C3-C6-cycloalkyl which can be substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl,
      or
    • a -CH=CH- group which is substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl,

    R7 represents trifluoromethyl or nitro,
    and
    Y1, Y2, Y3, Y4 and Y5 each represent CH.
  • The compounds according to this invention can also be present in the form of their salts, hydrates and/or solvates.
  • Physiologically acceptable salts are preferred in the context of the present invention.
  • Physiologically acceptable salts according to the invention are non-toxic salts which in general are accessible by reaction of the compounds (I) with an inorganic or organic base or acid conventionally used for this purpose. Non-limiting examples of pharmaceutically acceptable salts of compounds (I) include the alkali metal salts, e.g. lithium, potassium and sodium salts, the alkaline earth metal salts such as magnesium and calcium salts, the quaternary ammonium salts such as, for example, triethyl ammonium salts, acetates, benzene sulphonates, benzoates, dicarbonates, disulphates, ditartrates, borates, bromides, carbonates, chlorides, citrates, dihydrochlorides, fumarates, gluconates, glutamates, hexyl resorcinates, hydrobromides, hydrochlorides, hydroxynaphthoates, iodides, isothionates, lactates, laurates, malates, maleates, mandelates, mesylates, methylbromides, methylnitrates, methylsulphates, nitrates, oleates, oxalates, palmitates, pantothenates, phosphates, diphosphates, polygalacturonates, salicylates, stearates, sulphates, succinates, tartrates, tosylates, valerates, and other salts used for medicinal purposes.
  • Hydrates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with water, such as for example hemi-, mono-, or dihydrates.
  • Solvates of the compounds of the invention or their salts are stoichiometric compositions of the compounds with solvents.
  • The present invention includes both the individual enantiomers or diastereomers and the corresponding racemates or diastereomeric mixtures of the compounds according to the invention and their respective salts. In addition, all possible tautomeric forms of the compounds described above are included according to the present invention. The diastereomeric mixtures can be separated into the individual isomers by chromatographic processes. The racemates can be resolved into the respective enantiomers either by chromatographic processes on chiral phases or by resolution.
  • In the context of the present invention, the substituents, if not stated otherwise, in general have the following meaning:
    • Alkyl in general represents a straight-chain or branched saturated hydrocarbon radical having 1 to 6, preferably 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, pentyl, isopentyl, hexyl, isohexyl. The same applies to radicals such as alkoxy, alkylamino, alkylthio, alkylcarbonyl, alkoxycarbonyl, alkoxycarbonylamino and the like.
    • Alkanediyl in general represents a straight-chain or branched divalent alkane radical having 1 to 6, preferably 1 to 4 carbon atoms. Non-limiting examples include 1,2-ethylene, 1,3-propylene, propane-1,2-diyl, propane-2,2-diyl, 1,4-butylene, butane-1,3-diyl, butane-2,4-diyl, pentane-2,4-diyl, 2-methyl-pentane-2,4-diyl.
    • Alkenediyl in general represents a straight-chain or branched divalent alkene radical having 2 to 6, preferably 2 to 4 carbon atoms, and up to three double bonds. Non-limiting examples include ethene-1,2-diyl, ethene-1,1-diyl, propene-1,1-diyl, propene-1,2-diyl, propene-1,3-diyl, propene-3,3-diyl, propene-2,3-diyl, but-2-ene-1,4-diyl, 1,3-butadiene-1,4-diyl, pent-2-ene-1,4-diyl, hex-2-ene-1,4-diyl.
    • Alkoxy illustratively and preferably represents methoxy, ethoxy, n-propoxy, isopropoxy, tert.-butoxy, n-pentoxy and n-hexoxy.
    • Arylalkoxy and phenylalkoxy in general represent a straight-chain or branched alkoxy radical which is substituted with an aryl or a phenyl group, respectively. Non-limiting examples include benzyloxy, naphthylmethoxy, 1-phenylethoxy, 2-phenylethoxy, 2-naphthylethoxy, 3-phenylpropoxy, 4-phenylbutoxy. The same applies to the radical phenylalkoxycarbonyl.
    • Alkenoxy illustratively and preferably represents allyloxy, but-2-en-1-oxy, pent-3-en-1-oxy and hex-2-en-1-oxy.
    • Alkylcarbonyl in general represents a straight-chain or branched hydrocarbon radical having 1 to 6, preferably 1 to 4 carbon atoms which has a carbonyl function at the position of attachment. Non-limiting examples include formyl, acetyl, n-propionyl, n-butyryl, isobutyryl, pivaloyl, n-hexanoyl.
    • Alkylcarbonylamino in general represents a straight-chain or branched hydrocarbon radical having 1 to 6, preferably 1 to 4 carbon atoms which has a carbonylamino (-CO-NH-) function at the position of attachment and which is bonded to the carbonyl group. Non-limiting examples include formylamino, acetylamino, n-propionylamino, n-butyrylamino, isobutyrylamino, pivaloylamino, n-hexanoylamino.
    • Alkoxycarbonyl illustratively and preferably represents methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl, tert.-butoxycarbonyl, n-pentoxycarbonyl and n-hexoxycarbonyl.
    • Alkenoxycarbonyl illustratively and preferably represents allyloxycarbonyl, *but-2-en-1-oxycarbonyl, pent-3-en-1-oxycarbonyl and hex-2-en-1-oxycarbonyl.
    • Alkylamino represents an alkylamino radical having one or two (independently selected) alkyl residues, illustratively and preferably representing methylamino, ethylamino, n-propylamino, isopropylamino, tert.-butylamino, n-pentylamino, n-hexylamino, N,N-dimethylamino, N,N-diethylamino, N-ethyl-N-methylamino, N-methyl-N-n-propylamino, N-isopropyl-N-n-propylamino, N-tert-butyl-N-methylamino, N-ethyl-N-n-pentylamino and N-n-hexyl-N-methylamino.
    • Alkylaminocarbonyl represents an alkylaminocarbonyl radical having one or two (independently selected) alkyl residues, illustratively and preferably representing methylaminocarbonyl, ethylaminocarbonyl, n-propylaminocarbonyl, isopropylaminocarbonyl, tert.-butylaminocarbonyl, n-pentylaminocarbonyl, n-hexylaminocarbonyl, N,N-dimethylaminocarbonyl, N,N-diethylaminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-methyl-N-n-propylaminocarbonyl, N-isopropyl-N-n-propylaminocarbonyl, N-tert.-butyl-N-methylaminocarbonyl, N-ethyl-N-n-pentylamino-carbonyl and N-n-hexyl-N-methylaminocarbonyl.
    • Alkylsulfonyl in general represents a straight-chain or branched hydrocarbon radical having 1 to 6, preferably 1 to 4 carbon atoms which has a sulfonyl function at the position of attachment. Non-limiting examples include methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, tert.-butylsulfonyl.
    • Cycloalkyl in general represents a cyclic saturated hydrocarbon radical having 3 to 8, preferably 3 to 6 carbon atoms. Non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl. The same applies to radicals such as cycloalkylcarbonyl.
    • Aryl in general represents a mono- to tricyclic aromatic carbocyclic radical having 6 to 14, preferably 6 to 10 carbon atoms, illustratively and preferably representing phenyl, naphthyl and phenanthrenyl. The same applies to radicals such as arylcarbonyl, arylalkoxy and arylaminocarbonyl.
    • Arylcarbonyl illustratively and preferably represents benzoyl and naphthoyl.
    • Arylaminocarbonyl illustratively and preferably represents phenylaminocarbonyl and naphthylaminocarbonyl.
    • Heteroaryl per se and in heteroarylcarbonyl in general represents an aromatic mono- or bicyclic radical having 5 to 10 and preferably 5 or 6 ring atoms, and up to 5 and preferably up to 4 heteroatoms selected from the group consisting of S, O and N, illustratively and preferably representing thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, isothiazolyl, isoxazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, indazolyl, benzofuranyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl.
    • Heteroarylcarbonyl illustratively and preferably represents thienylcarbonyl, furylcarbonyl, pyrrolylcarbonyl, thiazolylcarbonyl, oxazolylcarbonyl, isothiazolylcarbonyl, isoxazolylcarbonyl, imidazolylcarbonyl, pyridylcarbonyl, pyrimidylcarbonyl, pyridazinylcarbonyl, indolylcarbonyl, indazolylcarbonyl, benzofuranylcarbonyl, benzothienylcarbonyl, quinolinylcarbonyl, isoquinolinylcarbonyl.
    • Heterocyclyl per se and in heterocyclylcarbonyl in general represents a mono- or polycyclic, preferably mono- or bicyclic, non-aromatic heterocyclic radical having 4 to 10 and preferably 5 to 8 ring atoms, and up to 3 and preferably up to 2 heteroatoms and/or hetero-groups selected from the group consisting ofN, O, S, SO and SO2. The heterocyclyl radicals can be saturated or partially unsaturated. Preference is given to 5- to 8-membered monocyclic saturated heterocyclyl radicals having up to two heteroatoms selected from the group consisting of O, N and S, such as illustratively and preferably tetrahydrofuran-2-yl, 1,3-dioxolan-4-yl, pynolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, perhydroazepinyl.
    • Heterocyclylcarbonyl illustratively and preferably represents tetrahydrofuran-2-carbonyl, 1,3-dioxolan-4-carbonyl, pyrrolidin-1-carbonyl, pyrrolidin-2-carbonyl, pyrrolidin-3-carbonyl, pyrrolincarbonyl, piperidincarbonyl, morpholincarbonyl, perhydroazepincarbonyl.
    • Halogen represents fluorine, chlorine, bromine and iodine.
  • When stated, that Y 1 , Y 2 , Y 3 , Y 4 and Y 5 represent CH or N, CH shall also stand for a ring carbon atom, which is substituted with a substituent R3 or R7.
  • A* symbol next to a bond denotes the point of attachment in the molecule.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein A is phenyl or pyridyl.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein R1 is hydrogen.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein R2 is cyano, especially wherein A is phenyl or pyridyl and R2 is cyano located in para-position relative to the central dihydropyrimidinone ring.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein R3 is hydrogen.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein R5 is methyl.
  • In another likewise preferred embodiment, the present invention relates to compounds according to general formula (I), wherein R7 is trifluoromethyl or nitro, especially wherein R7 is trifluoromethyl located in meta-position relative to the central dihydropyrimidinone ring.
  • In another likewise particularly preferred embodiment, the present invention relates to compounds of general formula (IA)
    Figure imgb0003
     wherein
    • Z represents CH or N, and
    • R1, R3, R4 and R6 have the meaning indicated above.
  • The compounds of the present invention, wherein R6 is hydrogen, can enolize into the corresponding hydroxyamidines:
    Figure imgb0004
  • In another embodiment, the present invention relates to a process for synthesizing the compounds of general formula (I) or (IA), respectively.
  • The compounds of general formula (I) or (IA), respectively, can be synthesized by condensing compounds of general formula (II)
    Figure imgb0005
     wherein A, R1 and R2 have the meaning indicated above,
    with compounds of general formula (III)
    Figure imgb0006
     wherein R4 and R5 have the meaning indicated above,
    and compounds of general formula (IV)
    Figure imgb0007
     wherein R3, R7, and Y1 to Y5 have the meaning indicated above,
    in the presence of an acid or acid anhydride either in a three-component / one-step reaction or sequentially to give compounds of general formula (IB)
    Figure imgb0008
     wherein A, R1 to R5, R7, and Y1 to Y5 have the meaning indicated above,
    optionally followed, in case R6 does not represent hydrogen, by reaction of the compounds of general formula (IB) with compounds of general formula (V)

            R6*-X     (V),

    wherein
    • R6*
    has the meaning of R6 as indicated above, but does not represent hydrogen, and
    X
    represents a leaving group, such as halogen, tosylate, mesylate or sulfate,
    in the presence of a base.
  • Suitable solvents for the process (II) + (III) + (IV) → (IB) are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, diisopropyl ether, methyl t-butyl ether, 1,2-dimethoxyethane, dioxan or tetrahydrofuran, ethyl acetate, acetone, acetonitrile, dimethylsulfoxide, dimethylformamide, or alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or t-butanol, or hydrocarbons such as pentane, hexane, cyclohexane, benzene, toluene or xylene, or halogeno-hydrocarbons such as dichloromethane, dichloroethane, trichloromethane or chlorobenzene. It is also possible to use mixtures of the above-mentioned solvents. Preferred for the process is tetrahydrofuran or dioxan.
  • Suitable acids for the process (II) + (III) + (IV) → (IB) are generally inorganic or organic acids or acid anhydrides. These preferably include carboxylic acids, such as, for example, acetic acid or trifluoroacetic acid, sulfonic acids, such as, for example, methanesulfonic acid or p-toluenesulfonic acid, hydrochloric acid, phosphoric or phosphonic acids or anhydrides, such as polyphosphoric acid or propanephosphonic acid anhydride. Preference is given to polyphosphoric acid ethyl ester. The acid is employed in an amount from 0.25 mol to 100 mol, relative to 1 mol of the compound of the general formula (III).
  • The process is in general carried out in a temperature range from +20°C to +150°C, preferably from +60°C to +100°C.
  • The process is generally carried out at normal pressure. However, it is also possible to carry it out at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).
  • Suitable solvents for the process (IB) + (V) → (I) are generally customary organic solvents which do not change under the reaction conditions. These include ethers such as diethyl ether, diisopropyl ether, 1,2-dimethoxyethane, dioxan or tetrahydrofuran, ethyl acetate, acetone, acetonitrile, dimethylsulfoxide, dimethylformamide, or hydrocarbons such as pentane, hexane, cyclohexane, benzene, toluene or xylene, or halogeno-hydrocarbons such as dichloromethane, dichloroethane, trichloromethane or chlorobenzene. It is also possible to use mixtures of the above-mentioned solvents. Preferred for the process is tetrahydrofuran or dimethylformamide.
  • Suitable bases for the process (IB) + (V) → (I) are generally inorganic or organic bases. These preferably include alkali carbonates such as sodium or potassium carbonate or hydrogencarbonate, cyclic amines such as, for example, N-methylmorpholine, N-methylpiperidine, pyridine or 4-N,N-dimethylaminopyridine, or (C1-C4)-trialkylamines such as, for example, triethylamine or diisopropylethylamine, or alkali hydrides such as sodium or potassium hydride. Preference is given to potassium carbonate or sodium hydride. The base is employed in an amount from 0.1 mol to 10 mol, preferably from 1 mol to 3 mol, relative to 1 mol of the compound of general formula (IV).
  • The process is in general carried out in a temperature range from 0°C to +150°C, preferably from +20°C to +80°C, especially at room temperature.
  • The process is generally carried out at normal pressure. However, it is also possible to carry it out at elevated pressure or at reduced pressure (for example in a range from 0.5 to 5 bar).
  • The compounds of the general formulas (II), (III), (IV) and (V) are known per se, or they can be prepared by customary methods.
  • The compounds of the present invention can also be prepared, if appropriate, by functional group transformations of individual substituents, especially those listed under R4 and R6, of the compounds of general formula (I) obtained by the process described above. These transformations are carried out using standard synthetic methods, e.g. by esterification, ester cleavage / hydrolysis, amide formation, catalytic hydrogenation, alkylation and/or aryl coupling reactions.
  • The above-mentioned method can be illustrated by the following scheme:
    Figure imgb0009
  • The compounds according to the invention exhibit an unforeseeable, useful pharmacological and pharmacokinetic activity spectrum. They are therefore suitable for use as medicaments for the treatment and/or prophylaxis of disorders in humans and animals.
  • Surprisingly, the compounds of the present invention show human neutrophil elastase (HNE) inhibitory activity and are therefore suitable for the preparation of medicaments for the treatment of diseases associated with HNE activity. They may thus provide an effective treatment of acute and chronic inflammatory processes, such as rheumatoid arthritis, atherosclerosis, and especially of acute and chronic pulmonary diseases, such as lung fibrosis, cystic fibrosis, pneumonia, acute respiratory distress syndrome (ARDS), in particular pulmonary emphysema, including smoking-induced emphysema, and chronic obstructive pulmonary diseases (COPD), chronic bronchitis and bronchiectasis. The compounds of the present invention may further provide an effective treatment for cardiovascular ischaemic diseases such as acute coronary syndrome, acute myocardial infarction, unstable and stable angina pectoris, coronary artery bypass grafts (CABG) and heart failure development, for atherosclerosis, mitral valvular disease, atrial septal defects, percutaneous transluminal coronary angioplasty (PTCA), inflammation after open heart surgery and for pulmonary hypertension. They may also prove useful for an effective treatment of rheumatoid arthritis, acute inflammatory arthritis, cancer, acute pancreatitis, ulcerative colitis, periodontal disease, Chury-Strauss syndrome, acute and chronic atopic dermatitis, psoriasis, systemic lupus erythematosus, bullous pemphigus, sepsis, alcoholic hepatitis, liver fibrosis, Behcet's disease, allergic fungal sinusitis, allergic sinusitis, Crohn's disease, Kawasaki disease, glomerulonephritis, acute pyelonephritis, colorectal diseases, chronic suppurative otitis media, chronic venous leg ulcers, inflammatory bowel disease, bacterial and viral infections, brain trauma, stroke and other conditions in which neutrophil participation is involved.
  • The present invention further provides medicaments containing at least one compound according to the invention, preferably together with one or more pharmacologically safe excipient or carrier substances, and also their use for the above-mentioned purposes.
  • The active component can act systemically and/or locally. For this purpose, it can be applied in a suitable manner, for example orally, parenterally, pulmonally, nasally, sublingually, lingually, buccally, rectally, transdermally, conjunctivally, otically or as an implant.
  • For these application routes, the active component can be administered in suitable application forms.
  • Useful oral application forms include application forms which release the active component rapidly and/or in modified form, such as for example tablets (non-coated and coated tablets, for example with an enteric coating), capsules, sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, solutions and aerosols.
  • Parenteral application can be carried out with avoidance of an absorption step (intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or with inclusion of an absorption (intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). Useful parenteral application forms include injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
  • Forms suitable for other application routes include for example inhalatory pharmaceutical forms (including powder inhalers, nebulizers), nasal drops/solutions, sprays; tablets or capsules to be administered lingually, sublingually or buccally, suppositories, ear and eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, milk, pastes, dusting powders or implants.
  • The active components can be converted into the recited application forms in a manner known per se. This is carried out using inert non-toxic, pharmaceutically suitable excipients. These include inter alia carriers (for example microcrystalline cellulose), solvents (for example liquid polyethylene glycols), emulsifiers (for example sodium dodecyl sulphate), dispersing agents (for example polyvinylpyrrolidone), synthetic and natural biopolymers (for example albumin), stabilizers (for example antioxidants such as ascorbic acid), colorants (for example inorganic pigments such as iron oxides) or taste and/or odor corrigents.
  • For human use, in the case of oral administration, it is recommendable to administer doses of from 0.001 to 50 mg/kg, preferably of 0.01 mg/kg to 20 mg/kg. In the case of parenteral administration, such as, for example, intravenously or via mucous membranes nasally, buccally or inhalationally, it is recommendable to use doses of 0.001 mg/kg to 0.5 mg/kg.
  • In spite of this, it can be necessary in certain circumstances to depart from the amounts mentioned, namely as a function of body weight, application route, individual behaviour towards the active component, manner of preparation and time or interval at which application takes place. It can for instance be sufficient in some cases to use less than the aforementioned minimum amount, while in other cases the upper limit mentioned will have to be exceeded. In the case of the application of larger amounts, it can be advisable to divide them into a plurality of individual doses spread through the day.
  • The percentages in the tests and examples which follows are, unless otherwise stated, by weight; parts are by weight. Solvent ratios, dilution ratios and concentrations reported for liquid/liquid solutions are each based on the volume.
    • A. Evaluation of physiological activity
  • The potential of the compounds of the invention to inhibit neutrophil elastase activity may be demonstrated, for example, using the following assays:
    • I. In vitro enzyme assays of human neutrophil elastase (HNE) Assay contents:
  • assay buffer: 0.1 M HEPES-NaOH buffer pH 7.4, 0.5 M NaCl, 0.1 % (w/v) bovine serum albumin;
    suitable concentration (see below) of HNE (18 U/mg lyophil., #20927.01, SERVA Electrophoresis GmbH, Heidelberg, Germany) in assay buffer;
    suitable concentration (see below) of substrate in assay buffer;
    suitable concentration of test compounds diluted with assay buffer from a 10 mM stock solution in DMSO.
    • Example I-A In vitro inhibition of HNE using a fluorogenic peptide substrate (continuous read-out signal, 384 MTP assay format):
  • In this protocol, the elastase substrate MeOSuc-Ala-Ala-Pro-Val-AMC (#324740, Calbiochem-Novabiochem Corporation, Merck KGaA, Darmstadt, Germany) is used. The test solution is prepared by mixing 10 µl of test compound dilution, 20 µl of HNE enzyme dilution (final concentration 8 - 0.4 µU/ml, routinely 2.1 µU/ml) and 20 µl of substrate dilution (final concentration 1 mM - 1 µM, routinely 20 µM), respectively. The solution is incubated for 0 - 2 hrs at 37°C (routinely one hour). The fluorescence of the liberated AMC due to the enzymatic reaction is measured at 37°C (TECAN spectra fluor plus plate reader). The rate of increase of the fluorescence (ex. 395 nm, em. 460 nm) is proportional to elastase activity. IC50 values are determined by RFU-versus-[I] plots. Km and Km(app.) values are determined by Lineweaver-Burk plots and converted to Ki values by Dixon plots.
  • The preparation examples have IC50 values within the range of 5 nM - 5 µM in this assay. Representative data are given in Table 1: Table 1
    Example No. IC50 [nM]
    1 20
    5 5
    6 200
    14 1000
    21 130
    43 23
    45 20
    69 50
    73 1000
    78 50
    • Example I-B In vitro inhibition of HNE using a fluorogenic, unsoluble elastin substrate (discontinuous read-out signal, 96 MTP assay format):
  • In this protocol the elastase substrate elastin-fluorescein (#100620, ICN Biomedicals GmbH, Eschwege, Germany) is used. The test solution is prepared by mixing 3 µl of test compound dilution, 77 µl of HNE enzyme dilution (final concentration 0.22 U/ml - 2.2 mU/ml, routinely 21.7 µU/ml) and 80 µl substrate suspension (final concentration 2 mg/ml). The suspension is incubated for 0 - 16 hrs at 37°C (routinely four hours) under slightly shaking conditions. To stop the enzymatic reaction, 160 µl of 0.1 M acetic acid are added to the test solution (final concentration 50 mM). The polymeric elastin-fluorescein is pulled down by centrifugation (Eppendorf 5804 centrifuge, 3.000 rpm, 10 min). The supernatant is transferred into a new MTP and the fluorescence of the liberated peptide fluorescein due to the enzymatic reaction is measured (BMG Fluostar plate reader). The rate of fluorescence (ex. 490 nm, em. 520 nm) is proportional to elastase activity. IC50 values are determined by RFU-versus-[I] plots.
    • II. In vitro human neutrophil assays Example II-A In vitro PMN elastolysis assay:
  • This assay is used to determine the elastolytic potential of human polymorphonuclear cells (PMNs) and assess the proportion of degradation due to neutrophil elastase [cf. Z.W. She et al., Am. J. Respir. Cell. Mol. Biol. 9, 386-392 (1993)].
  • Tritiated elastin, in suspension, is coated on to a 96 well plate at 10 µg per well. Test and reference [ZD-0892 (J. Med. Chem. 40, 1876-1885, 3173-3181 (1997), WO 95/21855 ) and α1 protease inhibitor (α1PI)] compounds are added to the wells at the appropriate concentrations. Human PMNs are separated from peripheral venous blood of healthy donors and resuspended in culture media. The neutrophils are added to the coated wells at concentrations ranging between 1 x 106 to 1 x 105 cells per well. Porcine pancreatic elastase (1.3 µM) is used as a positive control for the assay, and α1PI (1.2 µM) is used as the positive inhibitor of neutrophil elastase. The cellular control is PMNs without compound at each appropriate cell density. The cells plus compounds are incubated in a humidified incubator at 37°C for 4 hours. The plates are centrifuged to allow the harvest of cell supernatant only. The supernatant is transferred in 75 µl volumes to corresponding wells of a 96 well Lumaplate™ (solid scintillant containing plates). The plates are dried until no liquid is visible in the wells and read in a beta counter for 3 minutes per well.
  • Elastolysis of the 3H-elastin results in an increase in counts in the supernatant. An inhibition of this elastolysis shows a decrease, from the cellular control, of tritium in the supernatant. α1PI gave 83.46 ± 3.97% (mean ± s.e.m.) inhibition at 1.2 µM (n = 3 different donors at 3.6 x 105 cells per well). IC50 values were obtained for the reference compound ZD-0892 of 45.50 ± 7.75 nM (mean s.e.m.) (n = 2 different donors at 3.6 x 105 cells per well).
  • Given that ZD-0892 is a selective inhibitor of PMN elastase along with the data from α1PI inhibition, these results indicate that the majority of elastin degradation by PMNs is due to the release of neutrophil elastase, and not to another elastolytic enzyme such as matrix metalloproteases (MMPs). The compounds of this invention are evaluated for their inhibitory activity in this HNE-dependent model of neutrophil elastolysis.
    • Example II-B In vitro inhibition of membrane bound elastase:
  • Measurement of the inhibition of elastase bound to neutrophil membranes is performed using a human neutrophil assay. Neutrophils are stimulated with LPS at 37°C for 35 min and then spun at 1600 rpm. Subsequently, the membrane bound elastase is fixed to the neutrophils with 3% paraformaldehyde and 0.25% glutaraldehyde for 3 min at 4°C. The neutrophils are then spun, and vehicle and the compound under evaluation are added, followed by addition of the substrate MeOSuc-Ala-Ala-Pro-Val-AMC (#324740, Calbiochem-Novabiochem Corporation, Merck KGaA, Darmstadt, Germany) at 200 µM. Following a 25 min incubation at 37°C, the reaction is terminated with PMSF (phenylmethanesulfonyl fluoride), and the fluorescence is read at ex: 400 nm and em: 505 nm. IC50 values are determined by interpolation from plots of relative fluorescence vs. inhibitor concentration.
    • III. In vivo models Example III-A In vivo model of acute lung injury in the rat:
  • Instillation of human neutrophil elastase (HNE) into rat lung causes acute lung damage. The extent of this injury can be assessed by measuring lung haemorrhage.
  • Rats are anaesthetised with Hypnorm/Hypnovel/water and instilled with HNE or saline delivered by microsprayer into the lungs. Test compounds are administered by intravenous injection, by oral gavage or by inhalation at set times prior to the administration of HNE. Sixty minutes after the administration of elastase animals are killed by an anaesthetic overdose (sodium pentobarbitone) and the lungs lavaged with 2 ml heparinised phosphate buffered saline (PBS). Bronchoalveolar lavage (BAL) volume is recorded and the samples kept on ice. Each BAL sample is centrifuged at 900 r.p.m. for 10 minutes at 4-10°C. The supernatant is discarded and the cell pellet resuspended in PBS and the sample spun down again. The supernatant is again discarded and the cell pellet resuspended in 1 ml 0.1% cetyltrimethyl-ammonium bromide (CTAB) / PBS to lyse the cells. Samples are frozen until blood content is assayed. Prior to the haemorrhage assay the samples are defrosted and mixed. 100 µl of each sample are placed into a separate well of a 96 well flat-bottomed plate. All samples are tested in duplicate. 100 µl 0.1% CTAB/PBS is included as a blank. The absorbance of the well contents is measured at 415 nm using a spectrophotometer. A standard curve is constructed by measuring the OD at 415 nm of different concentrations of blood in 0.1% CTAB/PBS. Blood content values are calculated by comparison to the standard curve (included in each plate) and normalised for the volume of BAL fluid retrieved.
  • The compounds of this invention are evaluated intravenously, orally or by inhalation for their inhibitory activity in this model of HNE-induced haemorrhage in the rat.
    • Example III-B In vivo model of acute myocardial infarction in the rat:
  • Elastase inhibitors are tested in a rat thread infarct model. Male Wistar rats (weighing >300 g) receive 10 mg/kg aspirin 30 min prior to surgery. They are anaesthetized by isofluran and ventilated (120-130 strokes/min, 200-250 µl stroke volume; MiniVent Type 845, Hugo Sachs Elektronik, Germany) during the whole surgery. Following a left thoracotomy at the fourth intercostal space, the pericardium is opened and the heart briefly exteriorized. A thread is turned around the left coronary artery (LAD) without occluding the artery. The thread is passed under the skin to the neck of the animal. The thorax is closed and the animal is allowed to recover for 4 days. At the fifth day, rats are anaesthetized with ether for 3 min, and the thread is tied and the LAD occluded under ECG control. Test compounds are administered before or after LAD occlusion per os, intraperitoneally or intravenously (bolus or permanent infusion). After 1 hr occlusion, the thread is reopened to allow reperfusion. Hearts are excised, and infarct sizes are determined 48 hours later by staining of the re-occluded hearts with Evans blue, followed by TTC (triphenyltetrazolium chloride) staining of 2 mm heart sections. Normoxic (not occluded tissue) areas stain blue, ischemic (occluded but surviving tissue) areas stain red and necrotic (occluded dead tissue) areas remain white. Each tissue section is scanned and infarct sizes are determined by computer planimetry.
    • B. Examples Abbreviations:
    • aq.
    aqueous
    c
    concentration
    conc.
    concentrated
    DMF
    N,N-dimethylformamide
    DMSO
    dimethylsulfoxide
    EI
    electron impact ionisation (for MS)
    ESI
    electro-spray ionisation (for MS)
    h
    hour(s)
    HPLC
    high pressure liquid chromatography
    LC-MS
    liquid chromatography coupled with mass spectroscopy
    min
    minute(s)
    Mp.
    melting point
    MS
    mass spectroscopy
    NMR
    nuclear magnetic resonance spectroscopy
    of th.
    of theoretical (yield)
    RP
    reverse phase (for HPLC)
    Rt
    retention time (for HPLC)
    THF
    tetrahydrofuran
    General methods:
  • All reactions are carried out under an argon atmosphere unless otherwise noted. Solvents are used as purchased from Aldrich without further purification. 'Silica gel' or 'Silica' refers to Silica gel 60 (0.040 mm-0.063 mm) from Merck KGaA company. Melting points are obtained with a Büchi 512 or similar melting point device and are uncorrected.
  • Compounds purified by preparative HPLC are purified over a RP18-column with acetonitrile and water as the eluent, using a 1:9 to 9:1 gradient.
    • LC-MS/HPLC methods: HPLC method 1
  • Instrument: HP 1100 with DAD detection; column: Kromasil RP-18, 60 mm x 2 mm, 3.5 µm; eluent A: 5 ml HClO4/l water, eluent B: acetonitrile; gradient: 0 min 2% B → 0.5 min 2% B → 4.5 min 90% B → 9 min 90% B; flow: 0.75 ml/min; oven: 30°C; UV detection: 210 nm.
    • LC-MS method 2
  • Instrument: Micromass Quattro LCZ with HPLC Agilent Series 1100; column: Grom-Sill20 ODS-4 HE, 50 mm x 2.0 mm, 3 µm; eluent A: 11 water + 1 ml 50% formic acid, eluent B: 1 I acetonitrile + 1 ml 50% formic acid; gradient: 0.0 min 100% A → 0.2 min 100% A → 2.9 min 30% A → 3.1 min 10% A → 4.5 min 10% A; oven: 55°C; flow: 0.8 ml/min; UV detection: 208-400 nm.
    • LC-MS method 3
  • Instrument MS: Micromass ZQ; Instrument HPLC: Waters Alliance 2795; column: Phenomenex Synergi 2µ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 1 water + 0.5 ml 50% formic acid, eluent B: 1 1 acetonitrile + 0.5 ml 50% formic acid; gradient: 0.0 min 90% A → 2.5 min 30% A → 3.0 min 5% A → 4.5 min 5% A; flow: 0.0 min 1 ml/min → 2.5 min/3.0 min/4.5 min 2 ml/min; oven: 50°C; UV detection: 210 nm.
    • HPLC method 4
  • Instrument MS: Micromass ZQ; Instrument HPLC: HP 1100 Series with DAD detection; column: Phenomenex Synergi 2µ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 1 water + 0.5 ml 50% formic acid, eluent B: 1 1 acetonitrile + 0.5 ml 50% formic acid; gradient: 0.0 min 90% A → 2.5 min 30% A → 3.0 min 5% A → 4.5 min 5% A; flow: 0.0 min 1 ml/min → 2.5 min/3.0 min/4.5 min 2 ml/min; oven: 50°C; UV detection: 210 nm.
    • LC-MS method 5
  • Instrument: Micromass Quattro LCZ with HPLC Agilent Series 1100; column: Phenomenex Synergi 2µ Hydro-RP Mercury 20 mm x 4 mm; eluent A: 1 1 water + 0.5 ml 50% formic acid, eluent B: 1 1 acetonitrile + 0.5 ml 50% formic acid; gradient: 0.0 min 90% A → 2.5 min 30% A → 3.0 min 5% A → 4.5 min 5% A; flow: 0.0 min 1 ml/min → 2.5 min/3.0 min/4.5 min 2 ml/min; oven: 50°C; UV detection: 208-400 nm.
    • HPLC method 6
  • Instrument: HP 1100 with DAD detection; column: Kromasil RP-18, 60 mm x 2 mm, 3.5 µm; eluent A: 5 ml HClO4/l water, eluent B: acetonitrile; gradient: 0 min 2% B → 0.5 min 2% B → 4.5 min 90% B → 6.5 min 90% B; flow: 0.75 ml/min; oven: 30°C; UV detection: 210 nm.
    • Starting Materials and Intermediates: Example 1A Ethyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
  • Figure imgb0010
  • 7.0 g (34.29 mmol) N-[3-(trifluoromethyl)phenyl]urea, 8.99 g (68.58 mmol) 4-cyanobenzaldehyde, 8.92 g (68.58 mmol) ethyl 3-oxobutanoate and 20 g polyphosphoric acid ethyl ester are suspended in 250 ml of tetrahydrofuran. The mixture is stirred at reflux for 18 hours. After cooling down to room temperature, the solvent is removed in vacuo and the residue is purified by column chromatography on silica with cyclohexane/ethyl acetate as eluent.
  • Yield: 13.4 g (91 % of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.1 (t, 3H), 2.0 (s, 3H), 4.0 (q, 2H), 5.4 (d, 1H), 7.6 (m, 3H), 7.7 (m, 3H), 7.9 (m, 2H), 8.4 (d, 1H) ppm.
    • Example 2A. Allyl 4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0011
  • 45.0 g ethyl polyphosphate are dissolved in 150 ml dioxane, 15.0 g (73.5 mmol) N-[3-(trifluoromethyl)phenyl]urea, 19.3 g (147 mmol) 4-cyanobenzaldehyde and 20.9 g (147 mmol) allyl acetoacetate are added and the mixture is stirred under reflux overnight. Volatiles are evaporated in vacuo, the remainder is dissolved in ethyl acetate and sequentially washed with saturated aqueous sodium hydrogencarbonate, sodium hydrogensulfite and sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate).
  • Yield: 18.4 g (50% of th.)
    • 1H-NMR (400 MHz, DMSO-d6): δ = 2.08 (s, 3H), 4.55 (d, 2H), 5.05-5.18 (m, 2H), 5.41 (d, 1H), 5.82 (dddd, 1H), 7.54-7.92 (m, 8H), 8.41 (d, 1H) ppm. Example 3A Allyl (4R)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0012
  • The enantiomers of Example 2A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N-methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate → methanol → ethyl acetate; flow 50 ml/min; temperature 24°C; detection 280 nm].
  • 1H-NMR (400 MHz, DMSO-d6): δ = 2.08 (s, 3H), 4.55 (d, 2H), 5.05-5.18 (m, 2H), 5.41 (d, 1H), 5.82 (dddd, 1H), 7.54-7.92 (m, 8H), 8.41 (d, 1H) ppm.
  • [α]20 = +25.9° (λ = 589 nm, methanol, c = 540 mg / 100 ml).
    • Example 4A 4-{5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl}-benzonitrile
  • Figure imgb0013
  • 30 g (147 mmol) N-[3-(trifluoromethyl)phenyl]urea, 19.3 g (147 mmol) 4-cyanobenzaldehyde and 14.7 g (147 mmol) 2,4-pentanedione are suspended in 300 ml of tetrahydrofuran, and 90 g polyphosphoric acid ethyl ester are added. The mixture is stirred at reflux for 4 hours. After cooling down to room temperature, the solvent is removed in vacuo, the remainder is dissolved in ethyl acetate and sequentially washed with saturated aqueous sodium hydrogencarbonate and sodium chloride solution. The organic phase is dried over magnesium sulfate, filtered and evaporated to dryness in vacuo. The crude product is purified by column chromatography over silica gel (eluent: cyclohexane/ethyl acetate).
  • Yield: 16.8 g (29% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 2.0 (s, 3H), 2.2 (s, 3H), 5.5 (d, 1H), 7.5 (m, 1H), 7.6 (m, 3H), 7.7 (m, 1H), 7.8 (m, 1H), 7.9 (m, 2H), 8.5 (d, 1H) ppm.
    • Example 5A 4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidine-carboxylic acid
  • Figure imgb0014
    • Method A:
  • 3 g (7 mmol) of Example 1A are dissolved in a mixture of 50 ml water and 100 ml 5% potassium hydroxide in ethanol. The reaction mixture is stirred at room temperature for 18 hours. The solvent is removed in vacuo and the residue is purified by column chromatography on silica with dichloromethane/methanol as eluent.
  • Yield: 1.27 g (45% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 2.0 (s, 3H), 5.4 (d, 1H), 7.6 (m, 1H), 7.6 (m, 2H), 7.7 (m, 1H), 7.8 (m, 1H), 7.9 (m, 3H), 8.3 (d, 1H), 12.5 (s, 1H) ppm.
    • Method B:
  • 3.00 g (6.80 mmol) of Example 2A and 888 mg (10.2 mmol) morpholine are dissolved under argon in 30 ml tetrahydrofuran at room temperature. 392 mg (0.34 mmol) tetrakis(triphenylphosphine)-palladium(0) are added, and the mixture is reacted for 15 minutes at room temperature. The solvent is evaporated in vacuo, the remainder is dissolved in ethyl acetate and washed sequentially with 2 N hydrochloric acid, water and saturated sodium chloride solution. The organic phase is dried over magnesium sulfate and evaporated to dryness. The crude product is purified by preparative RP-HPLC with a water/acetonitrile gradient.
  • Yield: 1.51 g (52% of th.)
  • 1H-NMR: see above.
    • Example 6A (4R)-4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylic acid
  • Figure imgb0015
    • Method A:
  • The enantiomers of Example 5A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N-methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate → methanol → ethyl acetate; flow 25 ml/min; temperature 23°C; detection 254 nm].
  • 1H-NMR (300 MHz, DMSO-d6): δ = 2.0 (s, 3H), 5.4 (d, 1H), 7.6 (m, 1H), 7.6 (m, 2H), 7.7 (m, 2H), 7.8 (m, 1H), 7.9 (m, 2H), 8.3 (d, 1H), 12.5 (s, 1H) ppm.
  • [α]20 = +2.5° (λ = 589 nm, methanol, c = 505 mg / 100 ml).
    • Method B:
  • In analogy to Example 5A (method B), this compound is prepared from Example 3A in 87% yield.
    • Example 7A 2-Hydroxyethyl (4R)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-5-pyrimidinecarboxylate
  • Figure imgb0016
  • Under argon, 1560 mg (3.89 mmol) of Example 6A are added to 19.6 ml dimethylformamide. After addition of 1.095 ml (7.86 mmol) triethylamine and 1.11 ml (15.7 mmol) 2-bromoethanol, the reaction mixture is stirred at ca. 70°C for 8 hours. After cooling to room temperature, the reaction mixture is concentrated in vacuo. The residue is taken up in ethyl acetate and washed with water. After drying with magnesium sulfate, the organic phase is evaporated in vacuo. The residue is taken up in 8 ml methanol and purified by preparative HPLC (column: Nucleosil 100-5 C18 Nautilus, 20 x 50 mm, 5 µm; solvent A: acetonitrile, solvent B: water + 0.3% formic acid; gradient: 0 min 10% A → 2 min 10% A → 6 min 90% A → 7 min 90% A → 7.1 min 10% A → 8 min 10% A; wavelength: 220 nm; injection volume: ca. 500 µl; number of injections: 18). The product containing fractions are combined and lyophilized.
  • Yield: 1290 mg (74.5% of th.)
  • MS (EI): m/z = 446 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 2.05 (d, 3H), 3.5 (q, 2H), 3.95-4.15 (m, 2H), 4.75 (tr, 1H), 5.45 (d, 1H), 7.55-7.75 (m, 5H), 7.75 (d, 1H), 7.85 (d, 2H), 8.35 (d, 1H) ppm.
  • [α]20 = +14.3° (λ = 589 nm, methanol, c = 455 mg / 100 ml).
    • Example 8A 5-(Benzyloxy)-hexane-2,4-dione
  • Figure imgb0017
  • To a solution of ethyl 3-(benzyloxy)-2-methylpropanoate (13.4 g, 64 mmol) in dimethylsulfoxide (50 ml) is added sodium hydride (2.57 g, 64.34 mmol; 60% dispersion in mineral oil). After 5 minutes stirring, a solution of acetone (2.37 ml, 32.1 mmol) in dimethylsulfoxide (30 ml) is added, and the reaction is stirred at 60°C overnight. After cooling to room temperature, saturated aqueous ammonium chloride (100 ml) is added and the product is extracted with ethyl acetate (3 x 150 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by flash chromatography over silica gel 60 (300 g) using cyclohexane / ethyl acetate (10:1 to 5:1) as eluent. The title compound is isolated as a mixture of enol ethers.
  • Yield: 4.92 g (69% of th.)
  • HPLC (method 1): Rt = 4.17 min and 4.75 min, λmax = 280 nm
  • MS (ESIpos): m/z = 220 (M+H)+
    • Example 9A 1-Benzyl 2-ethyl piperidine-1,2-dicarboxylate
  • Figure imgb0018
  • To a stirred solution of ethyl piperidine-2-carboxylate (15 g, 95 mmol), triethylamine (27 ml, 191 mmol) and 4-dimethylaminopyridine (0.58 g, 4.8 mmol) in dichloromethane (100 ml) at 0°C is added a solution of benzyl chloridocarbonate (17 g, 100 mmol) dropwise. The reaction is allowed to warm slowly to room temperature. It is stirred at room temperature overnight (16 h), then allowed to stand for 2 days. The crude product is extracted with dichloromethane, washed with 1 N hydrochloric acid, saturated aqueous sodium bicarbonate solution and brine. The organic phase is dried with anhydrous magnesium sulfate, filtered and concentrated in vacuo. The residue is purified by flash chromatography over silica gel 60 (300 g) with cyclohexane / ethyl acetate as eluent to afford a pale yellow oil.
  • Yield: 17.9 g (62% of th.)
  • HPLC (method 6): Rt = 4.91 min, λmax = 202 nm
  • MS (ESIpos): m/z = 309 (M+NH4)+
    • Example 10A Benzyl 2-acetoacetylpiperidine-1-carboxylate
  • Figure imgb0019
  • The title compound is prepared according to the procedure described in Example 8A and is isolated as the enol ether.
  • Yield: 2.13 g (82% of th.)
  • HPLC (method 1): Rt = 4.45 and 4.98 min, λmax = 276 nm
  • MS (ESIpos): m/z = 321 (M+NH4)+
  • 1H-NMR (300 MHz, CDCl3): δ = 15.4 (br s, 1H), 7.45-7.20 (m, 5H), 5.62-4.68 (m, 3H), 4.29-3.63 (m, 2H), 3.15-2.80 (m, 1H), 2.37-1.10 (m, 6H), 2.01 (s, 3H) ppm.
    • Example 11A 2-(Benzyloxy)-1-[(benzyloxy)methyl]ethyl 3-oxobutanoate
  • Figure imgb0020
  • 1.00 g (3.67 mmol) 1,3-dibenzyloxy-2-propanol is dissolved in 10 ml toluene, 3.72 mg (0.04 mmol) triethylamine are added, and the mixture is stirred at 90°C. 401 mg (4.77 mmol) diketene are added, and stirring is continued for 1 h. The mixture is cooled to room temperature, diluted with ice-water and extracted with toluene. The organic layer is dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethylacetate 2:1).
  • Yield: 1.03 g (69% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 2.15 (s, 3H), 3.55-3.65 (m, 6H), 4.44 (dd, 2H), 5.67 (q, 1H), 7.23-7.40 (m, 10H) ppm.
    • Example 12A (1S)-2-(Benzyloxy)-1-methyl-2-oxoethyl 3-oxobutanoate
  • Figure imgb0021
  • In analogy to the procedure of Example 11A, the title compound is synthesized using (S)-benzyl lactate with a yield of 80% of th.
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.42 (d, 3H), 2.18 (s, 3H), 3.66 (s, 2H), 5.11 (q, 1H), 5.17 (s, 2H), 7.30-7.43 (m, 5H) ppm.
    • Example 13A Allyl 3-(2-tert.-butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0022
  • 1000 mg (2.27 mmol) of Example 2A are dissolved in 10 ml dimethylformamide, 344 mg (2.49 mmol) potassium carbonate and 486 mg (2.49 mmol) tert.-butyl bromoacetate are added, and the suspension is stirred at room temperature overnight. The mixture is partitioned between ethyl acetate and aqueous potassium dihydrogenphosphate/disodium hydrogenphosphate buffer (pH 7). The combined organic extracts are washed with water and aqueous sodium chloride solution, dried over magnesium sulfate, and evaporated in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 3:1).
  • Yield: 985 mg (78% ofth.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.29 (s, 9H), 2.08 (s, 3H), 3.88 (d, 1H), 4.09 (d, 1H), 4.52 (d, 2H), 5.09-5.15 (m, 2H), 5.60 (s, 1H), 5.71-5.92 (m, 1H), 7.60-7.93 (m, 8H) ppm.
    • Example 14A 3-(2-tert.-Butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid
  • Figure imgb0023
  • 985 mg (1.77 mmol) of Example 13A and 231 mg (2.66 mmol) morpholine are dissolved in 10 ml tetrahydrofuran at room temperature under an argon atmosphere. 102 mg (0.09 mmol) tetrakis-(triphenylphosphine)palladium(0) are added, and the solution is stirred for 30 minutes. The solvent is evaporated in vacuo, the remainder is dissolved in ethyl acetate and washed with 2 M hydrochloric acid, water and aqueous sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo. The crude product is purified using RP-HPLC with a water/acetonitrile gradient.
  • Yield: 662 mg (70% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.30 (s, 9H), 2.05 (s, 3H), 3.85 (d, 1H), 4.09 (d, 1H), 5.55 (s, 1H), 7.57-7.90 (m, 8H), 12.6 (br s, 1H) ppm.
    • Example 15A tert.-Butyl [6-(4-cyanophenyl)-5-(1H-imidazol-1-ylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-(2H)-yl]acetate
  • Figure imgb0024
  • 372 mg (0.72 mmol) of Example 14A are dissolved in 5 ml dimethylformamide, 351 mg (2.17 mmol) 1,1'-carbonyldiimidazole are added, and the mixture is stirred at room temperature overnight. The mixture is partitioned between water and ethyl acetate, the combined organic extracts are washed with aqueous sodium hydrogencarbonate solution, water and aqueous sodium chloride solution, dried over magnesium sulfate, filtered and evaporated to dryness in vacuo.
  • Yield: 392 mg (90% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.30 (s, 9H), 1.48 (s, 3H), 3.83 (d, 1H), 4.05 (d, 1H), 5.65 (s, 1H), 7.05 (s, 1H), 7.62 (s, 1H), 7.68-7.90 (m, 7H), 7.98 (s, 1H), 8.37 (s, 1H) ppm.
    • Example 16A 4-{5-[(1H-1,2,3-Benzotriazol-1-yloxy)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0025
  • 500 mg (1.25 mmol) of Example 5A, 310 mg (1.62 mmol) 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimid-hydrochloride and 202 mg (1.49 mmol) 1-hydroxybenzotriazole are dissolved in 2 ml dimethylformamide and stirred at room temperature overnight. The reaction mixture is partitioned between ethyl acetate and water, the organic phase is washed with saturated sodium chloride solution, dried over magnesium sulfate and evaporated to dryness in vacuo. The crude product is used directly for further reactions.
  • Yield: 580 mg (76% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 2.17 (s, 3H), 5.82 (d, 1H), 7.23 (d, 1H), 7.35-8.03 (m, 10H), 8.10 (d, 1H), 8.82 (d, 1H) ppm.
    • Example 17A Tribenzyl 2-{4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}ethane-1,1,1-tricarboxylate
  • Figure imgb0026
  • 200 mg (0.52 mmol) of Example 1, 259 mg (0.62 mmol) tribenzyl methanetricarboxylate and 203 mg (0.77 mmol) triphenylphosphine are dissolved in 3 ml tetrahydrofuran under an argon atmosphere. The solution is cooled to 0°C, and 156 mg (0.77 mmol) diisopropyl azodicarboxylate are added slowly. The mixture is warmed to room temperature overnight, evaporated to dryness and purified directly by vacuum flash chromatography on silica (eluent: petrol ether/ethyl acetate 2:1 → 1:1) and thereafter by RP-HPLC (eluent: acetonitrile/water gradient).
  • Yield: 60 mg (14% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.32 (s, 3H), 2.74 (d, 1H), 3.21 (d, 1H), 4.80 (d, 1H), 5.16 (s, 6H), 7.18-7.33 (m, 15H), 7.38 (d, 1H), 7.46 (s, 1H), 7.54 (d, 2H), 7.62 (t, 1H), 7.70 (d, 1H), 7.32-7.38 (m, 3H) ppm.
    • Example 18A (4R)-4-{5-Acetyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro-4-pyrimidinyl}-benzonitrile
  • Figure imgb0027
  • The enantiomers of Example 4A are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on monomer N-methacryloyl-L-leucine-1-menthylamide, cf. EP-A-379 917 ; 250 mm x 20 mm; eluent: ethyl acetate → methanol → ethyl acetate; flow 25 ml/min; temperature 23°C; detection 254 nm].
  • 1H-NMR (200 MHz, DMSO-d6): δ = 2.0 (s, 3H), 2.2 (s, 3H), 5.5 (d, 1H), 7.5 (m, 1H), 7.6 (m, 3H), 7.7 (m, 1H), 7.8 (m, 1H), 7.9 (m, 2H), 8.5 (d, 1H) ppm.
  • [α]20 =+45.9° (λ = 589 nm, methanol, c = 530 mg /100 ml).
    • Example 19A (4R)-Tribenzyl 2-{4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl} ethane-1,1,1-tricarboxylate
  • Figure imgb0028
  • 1.0 g (2.58 mmol) of Example 4, 1.3 g (3.10 mmol) tribenzyl methanetricarboxylate and 1.02 g (3.87 mmol) triphenylphosphine are dissolved in 15 ml tetrahydrofuran under an argon atmosphere. The solution is cooled to 0°C, and 0.67 g (3.87 mmol) diisopropyl azodicarboxylate are added slowly. The mixture is warmed to room temperature overnight, evaporated to dryness and purified directly by vacuum flash chromatography on silica (eluent: cyclohexane/ethyl acetate 2:1 → 1:1).
  • Yield: 0.65 mg (31% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.3 (s, 3H), 2.7 (d, 1H), 3.2 (d, 1H), 4.8 (d, 1H), 5.2 (s, 6H), 7.2 (m, 6H), 7.3 (m, 9H), 7.4 (m, 1H), 7.5 (m, 1H), 7.5 (m, 2H), 7.6 (m, 1H), 7.7 (m, 1H), 7.8 (m, 3H) ppm.
    • Example 20A 1-(2,2-Dimethyl-1,3-dioxolan-4-yl)-butane-1,3-dione
  • Figure imgb0029
  • To sodium hydride (3.7 g, 93 mmol; 60% dispersion in mineral oil) under an argon atmosphere is added DMSO (30 ml) followed by a solution of methyl 2,2-dimethyl-1,3-dioxolane-4-carboxylate (15 g, 93 mmol) in DMSO (50 ml). A solution of acetone (2.7 g, 45 mmol) in DMSO (50 ml) is then added dropwise over 1 hour. The solution is stirred at room temperature for 16 h, then quenched with saturated aqueous ammonium chloride solution (350 ml) and extracted with diethyl ether (11). The ether layer is washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude product is chromatographed over silica gel 60 with dichloromethane as eluent. The compound is isolated as its enol ether.
  • Yield: 3.98 g (46% of Th.)
  • 1H-NMR (300 MHz, CDCl3): δ = 5.90 (s, 1H), 4.56-4.44 (m, 1H), 4.32-4.23 (m, 1H), 4.04-3.96 (m, 1H), 2.11 (s, 3H), 1.49 (s, 3H), 1.41 (s, 3H) ppm.
    • Preparation Examples: Example 1 4-{5-(Hydroxymethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0030
  • 2.05 g (4.77 mmol) of Example 1A are dissolved in 40 ml tetrahydrofuran. At 0°C, 9.55 ml (9.55 mmol) of 1 M lithium aluminiumhydride in tetrahydrofuran are added dropwise. The solution is stirred at 0°C for two hours and then quenched with methanol. The solvent is removed in vacuo and the residue is purified by column chromatography on silica with dichloromethane/methanol mixtures as eluent.
  • Yield: 1.08 g (58% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.5 (s, 3H), 3.7 (dd, 1H), 4.1 (dd, 1H), 4.8 (dd, 1H), 5.1 (d, 1H), 7.5-7.7 (m, 6H), 7.9 (m, 3H) ppm.
    • Examples 2 and 3 4-{5-(1-Hydroxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0031
  • 200 mg (0.5 mmol) of Example 4A and 49 mg (0.6 mmol) sodium acetate are dissolved in 5 ml ethanol. 47 mg (1.25 mmol) sodium borohydride are added. The solution is stirred at room temperature for 16 hours, then water is added. The product precipitates as mixture of diastereomers (94 mg). The diastereomers are separated by preparative HPLC.
    • Example 2 (Diastereomer I):
  • Yield: 52 mg (26% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 0.8 (d, 3H), 1.6 (s, 3H), 4.6 (m, 1H), 4.9 (d, 1H), 5.1 (d, 1H), 7.5-7.7 (m, 6H), 7.8 (d, 1H), 7.9 (m, 2H) ppm.
    • Example 3 (Diastereomer II):
  • Yield: 41 mg (20% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.2 (d, 3H), 1.6 (s, 3H), 4.6 (m, 2H), 4.9 (d, 1H), 7.5 (m, 2H), 7.6 (m, 4H), 7.8 (m, 2H), 7.9 (d, 1H) ppm.
    • Example 4 (4R)-4-{-5-(Hydroxymethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0032
  • 3.00 g (6.80 mmol) of Example 3A are dissolved in 20 ml dry tetrahydrofuran, 6.80 ml (6.80 mmol) of 1 M lithium aluminiumhydride in tetrahydrofuran are added slowly, and stirring is continued for 30 minutes at 0°C. Saturated ammonium chloride solution is added cautiously to hydrolyze excess of lithium aluminiumhydride, followed by 50 ml ethyl acetate and dropwise addition of water to precipitate inorganic salts. The organic phase is decanted, washed with water, dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography over silica gel (eluent: dichloromethane/methanol 100:0 → 95:5).
  • Yield: 1.38 g (40% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.55 (s, 3H), 3.67 (dd, 1H), 4.10 (dd, 1H), 4.77 (t, 1H), 5.09 (d, 1H), 7.50 (d, 1H), 7.55-7.75 (m, 5H), 7.82 (d, 1H), 7.87 (d, 2H) ppm.
    • Example 5 (4R)-[5-{[2-(Carboxymethoxy)ethoxy]carbonyl}-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0033
  • 80 mg (0.18 mmol) of Example 7A are dissolved in 4 ml tetrahydrofuran, and 36 mg (0.9 mmol) sodium hydride (60% suspension in mineral oil) are added. After stirring for one hour at room temperature, 50 mg (0.36 mmol) bromoacetic acid are added. After stirring at room temperature for four hours, the mixture is quenched with methanol, the solvent is removed in vacuo and the residue is purified by preparative HPLC.
  • Yield: 21 mg (2 1 % of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 2.0 (s, 3H), 2.9 (d, 1H), 3.5-3.7 (m, 3H), 4.0 (m, 2H), 4.3 (m, 2H), 5.9 (s, 1H), 7.6-7.7 (m, 6H), 7.8 (m, 3H) ppm.
    • Example 6 4-(4-Cyanophenyl)-N-cyclopropyl-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxamide
  • Figure imgb0034
  • 100 mg (0.25 mmol) of Example 5A are dissolved in 2 ml tetrahydrofuran, and 3 mg (0.02 mmol) 4-N,N-dimethylaminopyridine, 39 mg (0.3 mmol) N,N-diisopropylethylamine and 156 mg (0.3 mmol) benzotriazol-1-yloxy-tris(pyrrolidino)phosphonium hexafluorophosphate are added. The reaction mixture is stirred at room temperature for 15 minutes, then 29 mg (0.5 mmol) cyclopropylamine are added. The reaction mixture is stirred at room temperature for 72 hours. The mixture is evaporated to dryness in vacuo and the crude product is purified by preparative HPLC.
  • Yield: 71 mg (62% ofth.)
  • LC-MS (method 2): Rt = 3.98 min
  • MS (ESIpos): m/z = 441 (M+H)+.
  • In analogy to the procedure for Example 6, the following compounds are prepared:
    Example No. Structure Starting materials Yield [%] Rt [min] (method) Mass [M+H]+
    7
    Figure imgb0035
         		Example 5A; 1-(3,4-dichloro-phenyl)-piperazine 61 4.32 (2) 614
    8
    Figure imgb0036
         		Example 5A; 1-benzyl-piperidin-4-amine 26 3.49 (2) 574
    9
    Figure imgb0037
         		Example 5A; methyl piperazine-1-carboxylate 66 3.96 (2) 528
    10
    Figure imgb0038
         		Example 5A; 1-pyridin-4-yl-piperazine 30 3.34 (2) 547
    11
    Figure imgb0039
         		Example 5A; 1-(2-chloro-phenyl)methan-amine 44 4.20 (2) 525
    12
    Figure imgb0040
         		Example 5A; 2-fluoroaniline 20 4.24 (2) 495
    13
    Figure imgb0041
         		Example 5A; 2-(2-fluoro-phenyl)ethan-amine 59 4.19 (2) 523
    14
    Figure imgb0042
         		Example 5A; 1-(2-fluoro-phenyl)methan-amine 56 4.15 (2) 509
    15
    Figure imgb0043
         		Example 5A; 1,4'-bipiperidine 23 3.35 (2) 552
    16
    Figure imgb0044
         		Example 5A; 1 propyl-piperazine 64 3.24 (2) 514
    17
    Figure imgb0045
         		Example 5A; ethyl piperidine-4-carboxylate 73 4.10 (2) 541
    • Examples 18 and 19 4-{5-[2-(Benzyloxy)propanoyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0046
  • To a stirred solution of 5-(benzyloxy)hexane-2,4-dione (250 mg, 1.13 mmol; Example 8A), 4-cyanobenzaldehyde (149 mg, 1.13 mmol) and N-[3-(trifluoromethyl)phenyl]urea (232 mg, 1.13 mmol) in tetrahydrofuran (5 ml) is added polyphosphoric acid ethyl ester (700 mg). After 16 hours, the reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10). The fractions containing product are concentrated and again purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
    • Example 18 (Diastereomer I):
  • Yield: 28 mg (4.75% of th.)
  • HPLC (method 1): Rt = 4.86 min, λmax = 234 nm
  • MS (ESIpos): m/z = 520 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.46 (d, 1H, J = 2.8 Hz), 7.93-7.12 (m, 13H), 5.59 (d, 1H, J = 2.8 Hz), 4.30-4.11 (m, 3H), 1.87 (s, 3H), 1.32-1.11 (m, 3H) ppm.
    • Example 19 (Diastereomer II):
  • Yield: 24.3 mg (4.12% of th.)
  • HPLC (method 1): Rt = 4.93 min, λmax = 232 nm
  • MS (ESIpos): m/z = 520 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.48 (d, 1H, J = 3.2 Hz), 7.90-7.13 (m, 13H), 5.48 (d, 1H, J = 2.8 Hz), 4.50-4.27 (m, 3H), 1.88 (s, 3H), 1.14 (d, 3H, J = 6.4 Hz) ppm.
    • Example 20 4-{5-(Cyclobutylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0047
  • To a stirred suspension of 1-cyclobutylbutane-1,3-dione (69 mg, 0.49 mmol), N-[3-(trifluoromethyl)phenyl]urea (100 mg, 0.49 mmol) and 4-cyanobenzaldehyde (64.2 mg, 0.49 mmol) in tetrahydrofuran (250 ml) is added polyphosphoric acid ethyl ester (300 mg). The reaction mixture is stirred at reflux for 18 hours. After cooling to room temperature, the solvent is removed in vacuo and the crude product is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
  • Yield: 54.6 mg (20% of th.)
  • LC-MS (method 5): Rt = 2.57 min
  • HPLC (method 6): Rt = 4.91 min, λmax = 200 nm
  • MS (ESIpos): m/z = 457 (M+NH4)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.39 (d, 1H, J = 3.7 Hz), 7.98-7.48 (m, 8H), 5.36 (d, 1H, J = 3.7 Hz), 3.56-3.43 (m, 1H), 2.22-1.40 (m, 6H), 1.94 (s, 3H) ppm.
    • Example 21 4-{5-(Cyclohexylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonithle
  • Figure imgb0048
  • The title compound is prepared according to the procedure described for Example 20.
  • Yield: 72.8 mg (27% of th.)
  • LC-MS (method 3): Rt = 2.63 min
  • HPLC (method 6): Rt = 5.18 min, λmax = 196 nm
  • MS (ESIpos): m/z = 485 (M+NH4)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.35 (d, 1H), 7.95-7.47 (m, 8H), 5.47 (d, 1H), 2.69 (m, 1H), 1.84 (s, 3H), 1.88-0.92 (m, 10H) ppm.
    • Example 22 4-{5-(Cyclopropylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0049
  • The title compound is prepared according to the procedure described for Example 18.
  • Yield: 113 mg (52% of th.)
  • LC-MS (method 5): Rt = 2.46 min
  • HPLC (method 6): Rt = 4.72 min, λmax = 202 nm
  • MS (ESIpos): m/z = 443 (M+NH4)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.38 (d, 1H, J = 3.6 Hz), 7.91-7.51 (m, 8H), 5.53 (d, 1H, J = 3.4 Hz), 3.56-3.43 (m, 1H), 1.98 (s, 3H), 0.93-0.72 (m, 4H) ppm.
    • Example 23 (4R)-4-{5-(Cyclopropylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0050
  • The enantiomers of Example 22 are separated by preparative HPLC on a chiral phase [chiral silica gel selector based on poly(N-methacryloyl-L-leucine-dicyclopropylmethylamide); column: 250 mm x 20 mm; gradient: 0-6 minutes ethyl acetate, 6-8 minutes methanol, 8-10 minutes ethyl acetate; flow: 25 ml/min; detection: UV 254 nm].
  • [α]20 = +32.0° (λ = 589 nm, methanol, c = 633 mg / 100 ml).
    • Example 24 4-{5-(4-Methoxybenzoyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-4-yl}benzonitrile
  • Figure imgb0051
  • The title compound is prepared according to the procedure described for Example 18.
  • Yield: 69.7 mg (28% of th.)
  • LC-MS (method 4): Rt = 2.58 min
  • HPLC (method 6): Rt = 4.83 min, λmax = 200 nm
  • MS (ESIpos): m/z = 492 (M+H)+
  • 1H-NMR (300 MHz, CDCl3): δ = 7.75-7.39 (m, 10H), 6.89 (d, 2H), 5.67 (m, 2H), 3.85 (s, 3H), 1.49 (s, 3H) ppm.
    • Example 25 4-{5-[(2-Amino-4-methyl-1,3-thiazol-5-yl)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2, 3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0052
  • The title compound is prepared according to the procedure described for Example 18.
  • Yield: 63 mg (26% of th.)
  • LC-MS (method 3): Rt = 2.22 min
  • MS (ESIpos): m/z = 498 (M+H)+
  • 1H-NMR (400 MHz, CDCl3): δ = 7.78-7.20 (m, 9H), 6.56-6.40 (m, 2H), 5.69 (br s, 1H), 2.24 (s, 3H), 1.93 (s, 3H) ppm.
    • Example 26 tert.-Butyl [6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidine-1(2H)-yl]acetate
  • Figure imgb0053
  • A stirred suspension of 4-{5-(cyclobutylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidm-4-yl}benzonitrile (Example 20) (29 mg, 0.066 mmol) and potassium carbonate (16.4 mg, 0.12 mmol) in dimethylformamide (1 ml) is treated with tert.-butyl bromoacetate (14.2 mg, 0.073 mmol), and then stirred at room temperature overnight (16 h). The reaction solution is quenched with water (3 ml) and extracted with diethyl ether (2 x 5 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated.
  • Yield: 40 mg (94.4% of th.)
  • LC-MS (method 4): Rt = 3.05 min
  • HPLC (method 1): Rt = 5.43 min, λmax = 234 nm
  • MS (ESIpos): m/z = 554 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.80-7.55 (m, 8H), 5.58 (br s, 1H), 4.19-3.91 (m, 2H), 3.60-3.47 (m, 1H), 2.40-0.85 (m, 6H), 1.94 (s, 3H), 1.26 (s, 9H) ppm.
    • Example 27 tert.-Butyl [6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0054
  • The title compound is prepared from Example 22 according to the procedure described for Example 26.
  • Yield: 89 mg (100% of th.)
  • LC-MS (method 4): Rt = 2.93 min
  • HPLC (method 1): Rt = 5.27 min, λmax = 200 nm
  • MS (ESIpos): m/z = 540 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.95-7.54 (m, 8H), 5.73 (s, 1H), 4.16-3.83 (m, 2H), 2.23 (m, 1H), 1.98 (s, 3H), 1.29 (s, 9H), 0.91-0.72 (m, 4H) ppm.
    • Example 28 tert.-Butyl [6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0055
  • The title compound is prepared from Example 21 according to the procedure described for Example 26.
  • Yield: 65 mg (90% of th.)
  • HPLC (method 1): Rt = 5.65 min, λmax = 234 nm
  • MS (ESIpos): m/z = 582 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.90-7.52 (m, 8H), 5.68 (s, 1H), 4.20-3.88 (m, 2H), 2.78-2.66 (m, 1H), 1.72 (s, 3H), 1.69-1.00 (m, 10H), 1.29 (s, 9H) ppm.
    • Example 29 tert.-Butyl [5-[(2-amino-4-methyl-1,3-thiazol-5-yl)carbonyl]-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0056
  • The title compound is prepared from Example 25 according to the procedure described for Example 26.
  • Yield: 38 mg (60% of th.)
  • LC-MS (method 4): Rt = 2.11 min
  • MS (ESIpos): m/z = 611 (M+H)+
  • 1H-NMR (300 MHz, CDCl3): δ = 7.75-7.20 (m, 8H), 6.28 (s, 1H), 5.96 (d, 1H), 5.62 (d, 1H), 4.72 (d, 1H), 4.55 (d, 1H), 1.47-1.35 (m, 15H) ppm.
    • Example 30 [6-(4-Cyanophenyl)-5-(cyclobutylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0057
  • tert.-Butyl [6-(4-cyanophenyl)-5-(cyclobutylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidine-1(2H)-yl]acetate (Example 26) (35 mg, 0.063 mmol) is dissolved in trifluoroacetic acid (1 ml). After 5 minutes stirring, the solution is concentrated in vacuo and the residue is purified by HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
  • Yield: 23.7 mg (65% ofth.)
  • LC-MS (method 4): Rt = 2.51 min
  • HPLC (method 1): Rt = 4.82 min, λmax = 234 nm
  • MS (ESIpos): m/z = 498 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.5 (br s, 1H), 7.96-7.54 (m, 8H), 5.61 (s, 1H), 4.19 (d, 1H), 3.85 (d, 1H), 2.30-1.60 (m, 7H), 1.91 (s, 3H) ppm.
    • Example 31 [6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0058
  • The title compound is prepared from Example 27 according to the procedure described for Example 30.
  • Yield: 27.1 mg (35% of th.)
  • LC-MS (method 3): Rt = 2.20 min
  • HPLC (method 6): Rt = 4.47 min, λmax = 234 nm
  • MS (ESIpos): m/z = 484 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 13.0 (br s, 1H), 7.93-7.53 (m, 8H), 5.76 (s, 1H), 4.23-3.71 (m, 2H), 2.26 (m, 1H), 1.98 (s, 3H), 0.96-0.73 (m, 4H) ppm.
    • Example 32 [6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-yl]acetic acid
  • Figure imgb0059
  • The title compound is prepared from Example 28 according to the procedure described for Example 30.
  • Yield: 18 mg (39% of th.)
  • LC-MS (method 4): Rt = 2.69 min
  • HPLC (method 6): Rt = 5.01 min, λmax = 236 nm
  • MS (ESIpos): m/z = 526 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.5 (br s, 1H), 7.99-7.50 (m, 8H), 5.70 (s, 1H), 4.25-3.74 (m, 2H), 2.75 (m, 1H), 1.85 (s, 3H), 1.78-0.80 (m, 10H) ppm.
    • Example 33 tert.-Butyl [6-(4-cyanophenyl)-5-(4-methoxybenzoyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0060
  • The title compound is prepared from Example 24 according to the procedure described for Example 26.
  • Yield: 141.2 mg (76% of th.)
  • HPLC (method 6): Rt = 5.36 min, λmax = 189 nm
  • MS (ESIpos): m/z = 606 (M+H)+
  • 1H-NMR (300 MHz, CDCl3): δ = 7.79-7.40 (m, 8H), 7.38 (d, 2H), 6.92 (d, 2H), 5.62 (s, 1H), 4.61 (d, 1H), 3.88 (s, 3H), 3.39 (d, 1H), 1.55 (s, 3H), 1.49 (s, 9H) ppm.
    • Example 34 [6-(4-Cyanophenyl)-5-(4-methoxybenzoyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidine-1(2H)-yl]acetic acid
  • Figure imgb0061
  • The title compound is prepared from Example 33 according to the procedure described for Example 30.
  • Yield: 81 mg (81% of th.)
  • LC-MS (method 3): Rt = 2.34 min
  • HPLC (method 6): Rt = 4.75 min, λmax = 200 nm
  • MS (ESIpos): m/z = 550 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.72 (br s, 1H), 7.96-7.54 (m, 10H), 6.98 (d, 2H), 5.66 (s, 1H), 4.21 (d, 1H), 3.81 (s, 3H), 3.19 (d, 1H), 1.41 (s, 3H) ppm.
    • Example 35 tert. -Butyl 3- {[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoro-methyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}benzoate
  • Figure imgb0062
  • Sodium hydride (12.1 mg, 0.31 mmol; 60% suspension in mineral oil) is washed with pentane (3 x 3 ml), then treated with a solution of 4-{5-(cyclopropylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile (Example 22) (100 mg, 0.235 mmol) in tetrahydrofuran (5 ml). After 5 minutes, the reaction is treated with a solution of tert.-butyl 3-(bromomethyl)benzoate (77 mg, 0.28 mmol) in tetrahydrofuran (5 ml) and then stirred at room temperature overnight (16 h). The reaction mixture is quenched with water (50 ml) and extracted with ethyl acetate (3 x 150 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated in vacuo. The crude product is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
  • Yield: 124 mg (84% ofth.)
  • LC-MS (method 3): Rt = 3.04 min
  • HPLC (method 6): Rt = 5.59 min, λmax = 198 nm
  • MS (ESIpos): m/z = 616 (M+H)+
  • 1H-NMR (300 MHz, CDCl3): δ = 7.93-7.83 (m, 2H), 7.73-7.58 (m, 4H), 7.54-7.35 (m, 6H), 5.50 (s, 1H), 5.21 (d, 1H), 4.00 (d, 1H), 2.01 (s, 3H), 1.94 (m, 1H), 1.60 (s, 9H), 1.08-0.79 (m, 4H) ppm.
    • Example 36 3-{[6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}benzoic acid
  • Figure imgb0063
  • The title compound is prepared from Example 35 according to the procedure described for Example 30, with the exception that the reaction time is 30 minutes, and the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90:10).
  • Yield: 67 mg (82% of th.)
  • LC-MS (method 4): Rt = 2.59 min
  • MS (ESIpos): m/z = 560 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.90 (br s, 1H), 7.86-7.35 (m, 12H), 5.68 (s, 1H), 4.90 (d, 1H), 4.30 (d, 1H), 2.21 (m, 1H), 1.95 (s, 3H), 0.95-0.76 (m, 4H) ppm.
    • Example 37 tert.-Butyl 4-({4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)piperidine-1-carboxylate
  • Figure imgb0064
  • The title compound is prepared according to the procedure described for Example 18.
  • Yield: 20 mg (2% of th.)
  • LC-MS (method 4): Rt = 2.73 min
  • HPLC (method 6): Rt = 5.09 min, λmax = 196 nm
  • MS (ESIpos): m/z = 569 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.40 (br d, 1H), 8.17-7.19 (m, 8H), 5.51 (br d, 1H), 4.00-3.70 (m, 1H), 3.03-2.39 (m, 3H), 1.85 (s, 3H), 1.80-1.66 (m, 2H), 1.37 (s, 9H), 1.56-1.00 (m, 2H) ppm.
    • Example 38 tert.-Butyl 3-{[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}benzoate
  • Figure imgb0065
  • The title compound is prepared from Example 21 according to the procedure described for Example 35.
  • Yield: 65 mg (46% of th.)
  • LC-MS (method 3): Rt= 3.31 min
  • MS (ESIpos): m/z = 658 (M+H)+
  • 1H-NMR (200 MHz, DMSO-d6): δ = 7.90-7.39 (m, 12 H), 5.58 (s, 1H), 4.97 (d, 1H), 4.31 (d, 1H), 2.67 (m, 1H), 1.80 (s, 3H), 1.52 (s, 9H), 1.70-0.85 (m, 10 H) ppm.
    • Example 39 tert.-Butyl 4-({3-(2-tert.-butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)piperidine-1-carboxylate
  • Figure imgb0066
  • A stirred suspension of tert.-butyl 4-({4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)piperidine-1-carboxylate (Example 37) (43 mg, 0.08 mmol) and potassium carbonate (19 mg, 0.14 mmol) in dimethylformamide (1.5 ml) is treated with tert.-butyl bromoacetate (16 mg, 0.08 mmol), then stirred at room temperature overnight (16 h). The reaction solution is then diluted with methanol (7 ml) and purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 10:90 → 90:10).
  • Yield: 26.5 mg (51% of th.)
  • LC-MS (method 3): Rt = 3.02 min
  • MS (ESIpos): m/z = 682 (M+H)+
  • HPLC (method 6): Rt = 5.44 min, λmax = 234 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.43-7.34 (m, 8H), 5.71 (s, 1H), 4.22-3.74 (m, 4H), 3.10-2.39 (m, 4H), 1.84 (s, 3H), 1.88-1.69 (m, 1H), 1.54-1.00 (s, 20H) ppm.
    • Example 40 3-{[6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}benzoic acid
  • Figure imgb0067
  • The title compound is prepared from Example 38 according to the procedure described for Example 30, with the exception that the reaction time is 30 minutes, and the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90:10).
  • Yield: 40 mg (77% of th.)
  • HPLC (method 6): Rt = 5.15 min, λmax = 200 nm
  • MS (ESIpos): m/z = 602 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.95 (s, 1H), 7.94-7.40 (m, 12H), 5.51 (s, 1H), 5.00 (d, 1H), 4.21 (d, 1H), 2.77-2.60 (m, 1H), 1.80 (s, 3H), 1.68-1.36 (m, 5H), 1.29-0.90 (m, 5H) ppm.
    • Example 41 Diethyl {4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}phosphonate
  • Figure imgb0068
  • A solution of diethyl (2-oxopropyl)phosphonate (250 mg, 1.29 mmol), 4-cyanobenzaldehyde (168.84 mg, 1.29 mmol), N-[3-(trifluoromethyl)phenyl]urea (263 mg, 1.29 mmol) and polyphosphoric acid ethyl ester (0.70 g) in tetrahydrofuran (5 ml) is refluxed overnight with stirring. The reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 10:90 → 90:10). The fractions containing product are concentrated in vacuo and repurified by flash chromatography on silica gel 60 with dichloromethane / methanol as eluent.
  • Yield: 20 mg (3% of th.)
  • HPLC (method 1): Rt = 4.31 min, λmax = 236 nm
  • MS (ESIpos): m/z = 494 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.39-8.27 (m, 1H), 7.07-7.48 (m, 8H), 4.98-4.84 (m, 1H), 3.79-3.19 (m, 4H), 2.50 (s, 3H), 1.05 (t, 3H), 0.95 (t, 3H) ppm.
    • Example 42 Methyl 5-{[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-2-furoate
  • Figure imgb0069
  • To a stirred suspension of 4-{5-(cyclopropylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile (Example 22) (150 mg, 0.35 mmol) and potassium carbonate (98 mg, 0.71 mmol) in dimethylformamide (3 ml) is added methyl 5-(chloromethyl)-2-furoate (92 mg, 0.53 mmol). The suspension is stirred at room temperature overnight (16 h), then additional methyl 5-(chloromethyl)-2-furoate (6.1 mg, 0.35 mmol) and potassium carbonate (49 mg, 0.35 mmol) are added, and the suspension is stirred an additional 72 hours. The reaction mixture is diluted with methanol (5 ml) and purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 10:90 → 90:10). The title compound is isolated as a brownish amorphous solid.
  • Yield: 72 mg (35% of th.)
  • LC-MS (method 4): Rt = 2.75 min
  • MS (ESIpos): m/z = 564 (M+H)+
  • HPLC (method 1): Rt = 4.98 min, λmax = 196 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.99-7.41 (m, 8H), 7.13 (d, 1H, J = 3.58 Hz), 6.47 (d, 1H, J = 3.58 Hz), 5.73 (s, 1H), 4.78 (d, 1H), 4.50 (d, 1H), 3.78 (s, 3H), 2.57-2.48 (m, 1H), 1.94 (s, 3H), 1.03-0.73 (m, 4H) ppm.
    • Example 43 Methyl 2-{[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-1,3-oxazole-4-carboxylate
  • Figure imgb0070
  • To a stirred suspension of 4-{5-(cyclopropylcarbonyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile (Example 22) (150 mg, 0.35 mmol) and potassium carbonate (98 mg, 0.71 mmol) in dimethylformamide (3 ml) is added methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate (93 mg, 0.53 mmol). The reaction mixture is stirred at room temperature overnight, then an additional equivalent of potassium carbonate (0.35 mmol) and methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate (0.35 mmol) are added, and the solution is stirred an additional 72 hours. The reaction mixture is quenched with water (20 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90:10).
  • Yield: 74 mg (37% of th.)
  • LC-MS (method 5): Rt = 2.61 min
  • MS (ESIpos): m/z = 565 (M+H)+
  • HPLC (method 1): Rt = 4.78 min, λmax = 196 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.68 (s, 1H), 7.92-7.48 (m, 8H), 5.84 (s, 1H), 4.91-4.51 (m, 2H), 3.79 (s, 3H), 2.37-2.23 (m, 1H), 1.96 (s, 3H), 0.96-0.72 (m, 4H) ppm.
    • Example 44 2-[6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]-N-[(4-cyanophenyl)sulfonyl]acetamide
  • Figure imgb0071
  • A mixture of [6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid (Example 31) (100 mg, 0.21 mmol), 1,3-dicyclohexylcarbodiimide (41.5 mg, 0.23 mmol), 4-cyanobenzene-1-sulfonamide (41.5 mg, 0.23 mmol) and 4-dimethylaminopyridine (28 mg, 0.23 mmol) in dichloromethane (4 ml) is stirred for 48 hours. The product is extracted with dichloromethane, washed with 2 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 10:90 → 90:10).
  • Yield: 45 mg (33% of th.)
  • LC-MS (method 3): Rt = 2.56 min
  • MS (ESIpos): m/z = 648 (M+H)+
  • HPLC (method 1): Rt = 4.83 min, λmax = 198 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.22-7.98 (m, 4H), 7.93-7.45 (m, 9H), 5.65 (s, 1H), 4.30-3.63 (m, 2H), 2.34-2.13 (m, 1H), 1.94 (s, 3H), 0.98-0.70 (m, 4H) ppm.
    • Example 45 2-[6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]-N-[(2,2,2-trifluoroethyl)sulfonyl]acetamide
  • Figure imgb0072
  • A mixture of [6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl) phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid (Example 31) (100 mg, 0.21 mmol), 2,2,2-trifluoroethanesulfonamide (37 mg, 0.23 mmol), 1,3-dicyclohexylcarbodiimide (47 mg, 0.23 mmol) and 4-dimethylaminopyridine (28 mg, 0.23 mmol) in dichloromethane (4 ml) is stirred for 48 hours. The crude product is extracted with dichloromethane (100 ml), washed with 2 N hydrochloric acid and brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by flash chromatography with silica gel 60 (50 g) and 2:1 cyclohexane/ethyl acetate as eluent.
  • Yield: 73 mg (56% of th.)
  • MS (ESIpos): m/z = 629 (M+H)+
  • HPLC (method 1): Rt = 4.84 min, λmax = 234 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.94-7.48 (m, 9H), 5.75 (s, 1H), 4.3 (d, 1H), 4.08 (q, 2H), 3.12 (d, 1H), 2.44-2.25 (m, 1H), 1.90 (s, 3H), 0.99-0.72 (m, 4H) ppm.
    • Example 46 Methyl 5-{[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-2-furoate
  • Figure imgb0073
  • The title compound is prepared from Example 21 according to the procedure described for Example 42, with the exception that only 1.5 equivalents of methyl 5-(chloromethyl)-2-furoate and 2 equivalents of potassium carbonate are used. The title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 30:70 → 90:10).
  • Yield: 65 mg (34% of th.)
  • LC-MS (method 4): Rt = 3.10 min
  • MS (ESIpos): m/z = 606 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.95-7.48 (m, 8H), 7.19 (m, 1H), 6.53 (m, 1H), 5.59 (s, 1H), 4.88 (d, 1H), 4.43 (d, 1H), 3.79 (s, 3H), 2.78-2.65 (m, 1H), 1.78 (s, 3H), 1.70-0.97 (m, 10H).
    • Example 47 Methyl 2- {[6-(4-cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-1,3-oxazole-4-carboxylate
  • Figure imgb0074
  • The title compound is prepared from Example 21 according to the procedure described for Example 43, with the exception that only 2 equivalents of potassium carbonate and 1.5 equivalents of methyl 2-(chloromethyl)-1,3-oxazole-4-carboxylate are used. The reaction time is 72 hours.
  • Yield: 80 mg (41% of th.)
  • LC-MS (method 4): Rt = 2.76 min
  • MS (ESIpos): m/z = 607 (M+H)+
  • HPLC (method 1): Rt = 5.41 min, λmax = 194 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.71 (s, 1H), 7.93-7.54 (m, 8H), 5.74 (s, 1H), 4.93 (d, 1H), 4.53 (d, 1H), 3.80 (s, 3H), 2.79-2.67 (m, 1H), 1.81 (s, 3H), 1.69-0.97 (m, 10H) ppm.
    • Example 48 5-{[6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-l (2H)-yl]methyl} -2-furoic acid
  • Figure imgb0075
  • A stirred solution of methyl 5-{[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-2-furoate (Example 42) (50 mg, 0.09 mmol) in tetrahydrofuran (1.5 ml) is treated with a solution of lithium hydroxide (2.34 mg, 0.1 mmol) in water (1.5 ml). After three hours stirring at room temperature, additional lithium hydroxide (2.34 mg, 0.1 mmol) is added. The reaction solution is stirred overnight (16 h), then allowed to stand for 48 h. The solution is acidified with 1 N hydrochloric acid (500 µl). After 5 minutes stirring, a precipitate is obtained. Methanol (3 ml) is added, and the crude reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90:10). The title compound is isolated as a brownish solid.
  • Yield: 27.5 mg (56.4% of th.)
  • HPLC (method 6): Rt = 4.71 min, λmax = 244 nm
  • MS (ESIpos): m/z = 550 (M+H)+
  • 1H-NMR (400 MHz, DMSO-d6): δ = 13.1 (br s, 1H), 7.90-7.76 (m, 4H), 7.74 (t, 1H), 7.63 (d, 1H), 7.51 (d, 2H), 7.03 (m, 1H), 6.45 (d, 1H), 5.72 (s, 1H), 4.84 (d, 1H), 4.38 (d, 1H), 2.2 (m, 1H), 1.95 (s, 3H), 0.98-0.75 (m, 4H) ppm.
    • Example 49 2-[6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]-N-[(4-cyanophenyl)sulfonyl]acetamide
  • Figure imgb0076
  • The title compound is prepared from Example 32 according to the procedure described for Example 44, with the exception that the title compound is purified by HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90: 10).
  • Yield: 65 mg (48% of th.)
  • LC-MS (method 3): Rt = 2.93 min
  • MS (ESIpos): m/z = 690 (M+H)+
  • HPLC (method 1): Rt = 5.28 min, λmax = 198 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.57 (br s, 1H), 8.06 (d of d, 4H), 7.84 (d, 2H), 7.75-7.62 (m, 3H), 7.58-7.49 (m, 3H), 5.56 (s, 1H), 4.16 (d, 1H), 3.86 (d, 1H), 2.64 (m, 1H), 1.79 (s, 3H), 1.68-0.93 (m, 10H) ppm.
    • Example 50 2-[6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]-N-[(2,2,2-trifluoroethyl)sulfonyl]acetamide
  • Figure imgb0077
  • The title compound is prepared from Example 32 according to the procedure described for Example 45, with the exception that the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/water 30:70 → 90:10).
  • Yield: 52 mg (40% of th.)
  • HPLC (method 1): Rt = 5.30 min, λmax = 238 nm
  • MS (ESIpos): m/z = 671 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.89 (d, 2H), 7.80 (d, 1H), 7.71 (t, 2H), 7.62 (d, 2H), 7.59 (s, 1H), 5.66 (s, 1H), 4.70-4.50 (m, 2H), 4.28 (d, 1H), 3.86 (d, 1H), 2.72 (m, 1H), 1.82 (s, 3H), 1.91-0.96 (m, 10H) ppm.
    • Example 51 2-{[6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-1,3-oxazole-4-carboxylic acid
  • Figure imgb0078
  • To a stirred solution of methyl 2-{[6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-1,3-oxazole-4-carboxylate (Example 43) (50 mg, 0.09 mmol) in tetrahydrofuran (1.5 ml) is added a solution of lithium hydroxide (4.24 mg, 0.18 mmol) in water (1.5 ml). The reaction solution is stirred at room temperature overnight (16 h). The pH of the solution is adjusted to less than pH 7 with 1 N hydrochloric acid (500 µl). After 5 minutes stirring, a precipitate is obtained. Methanol (3 ml) is added, and the crude reaction solution is purified directly by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 30:70 → 90:10). The title compound is isolated as a colourless solid.
  • Yield: 41 mg (84% of th.)
  • LC-MS (method 3): Rt = 2.22 min
  • MS (ESIpos): m/z = 551 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 13.01 (br s, 1H), 8.57 (s, 1H), 7.90-7.52 (m, 8H), 5.84 (s, 1H), 4.88 (d, 1H), 4.51 (d, 1H), 2.30 (m, 1H), 1.96 (s, 3H), 0-96-0.73 (m, 4H) ppm.
    • Example 52 5-{[6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-2-furoic acid
  • Figure imgb0079
  • The title compound is prepared from Example 46 according to the procedure described for Example 48, with the exception that the title compound is purified by preparative HPLC (RP18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
  • Yield: 43 mg (77% of th.)
  • HPLC (method 1): Rt = 5.20 min, λmax = 202 nm
  • LC-MS (method 4): Rt = 2.80 min
  • MS (ESIpos): m/z = 592 (M+H)+
  • 1H-NMR (300 MHz, DMSO-d6): δ = 13.0 (br s, 1H), 7.90-7.65 (m, 5H), 7.63-7.46 (m, 3H), 7.10 (d, 1H), 6.53 (d, 1H), 5.55 (s, 1H), 4.92 (d, 1H), 4.32 (d, 1H), 2.77-2.63 (m, 1H), 1.79 (s, 3H), 1.68-1.37 (m, 5H), 1.31-0.93 (m, 5H) ppm.
    • Example 53 2- {[6-(4-Cyanophenyl)-5-(cyclohexylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]methyl}-1,3-oxazole-4-carboxylic acid
  • Figure imgb0080
  • The title compound is prepared from Example 47 according to the procedure described for Example 51, with the exception that the title compound is purified by preparative HPLC (RP 18 column; eluent: acetonitrile/0.1% aq. formic acid 10:90 → 90:10).
  • Yield: 46 mg (84% of th.)
  • LC-MS (method 3): Rt = 2.52 min
  • MS (ESIpos): m/z = 593 (M+H)+
  • HPLC (method 1): Rt = 5.07 min, λmax = 194 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 13.0 (br s, 1H), 8.58 (s, 1H), 7.86 (d, 2H), 7.83-7.60 (m, 4H), 7.58 (d, 2H), 5.72 (s, 1H), 4.95 (d, 1H), 4.47 (d, 1H), 2.80-2.66 (m, 1H), 1.81 (s, 3H), 1.69-0.95 (m, 10H)ppm.
    • Example 54 Benzyl 2-({4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)piperidine-1-carboxylate
  • Figure imgb0081
  • A stirred mixture of benzyl 2-acetoacetylpiperidine-l-carboxylate (Example 10A) (1.74 g, 5.74 mmol), 4-cyanobenzaldehyde (752 mg, 5.74 mmol), N-[3-(trifluoromethyl)phenyl]urea (976 mg, 4.78 mmol) and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide anhydride (6.1 g, 9.5 mmol) in methyl tert.-butyl ether (44 ml) is refluxed overnight (16 h). The product is extracted with methyl tert.-butyl ether (300 ml), washed with aq. saturated sodium bicarbonate solution (200 ml), dried with anhydrous magnesium sulfate, filtered and concentrated. The residue is chromatographed with silica gel 60 using cyclohexane / ethyl acetate as eluent.
  • Yield: 858 mg (30% of th.)
  • HPLC (method 1): Rt = 5.16 min, λmax = 232 nm
  • MS (ESIpos): m/z = 603 (M+H)+
  • LC-MS (method 3): Rt = 2.66 min
  • 1H-NMR (300 MHz, CDCl3): δ = 7.8-7.1 (m, 14H), 5.80-4.80 (m, 3H), 4.2-3.8 (m, 1H), 3.3-2.9 (m, 2H), 1.5 (s, 3H), 2.1-0.8 (m, 6H) ppm.
    • Example 55 Benzyl 2-({3-(2-tert.-butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)piperidine-1-carboxylate
  • Figure imgb0082
  • The title compound is prepared from Example 54 according to the procedure described for Example 26.
  • Yield: 53 mg (18% of th.)
  • LC-MS (method 3): Rt = 3.08 min
  • HPLC (method 1): Rt = 5.62 min, λmax = 234 nm
  • MS (ESIpos): m/z = 712 (M+H)+
  • 1H-NMR (300 MHz, CDCl3): δ = 7.72-7.12 (m, 13H), 5.64-4.56 (m, 5H), 4.18-3.92 (m, 1H), 3.52-3.12 (m, 2H), 2.35-0.73 (m, 6H), 1.52 (s, 3H), 1.48 (s, 9H) ppm.
    • Example 56 [5-({1-[(Benzyloxy)carbonyl]piperidin-2-yl}carbonyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin- (2H)-yl]acetic acid
  • Figure imgb0083
  • The title compound is prepared from Example 55 according to the procedure described for Example 30.
  • Yield: 35 mg (84% of th.)
  • HPLC (method 1): Rt = 5.70 min, λmax = 254 nm
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.5 (br s, 1H), 7.91-7.01 (m, 13H), 5.86 (d, 1H), 5.40-5.25 (m, 1H), 5.08 (s, 1H), 5.00-4.76 (m, 1H), 4.27 (m, 1H), 3.93-3.68 (m, 1H), 1.75 (s, 3H), 1.9-0.7 (m, 8H) ppm.
  • In analogy to the procedure for Example 2A, the following compounds are prepared:
    Example No. Structure Starting material Yield [%] Rt [min] (method) Mass [M+H]+
    57
    Figure imgb0084
         		Example 11A 72 5.50(1) 656
    58
    Figure imgb0085
         		Example 12A 13 5.22 (6) 564
    • Example 59 Benzyl tert.-butyl ({4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}carbonyl)malonate
  • Figure imgb0086
  • 1401 mg (5.60 mmol) benzyl tert.-butyl malonate are dissolved in 4 ml tetrahydrofuran under an argon atmosphere. The solution is cooled to 0°C, 156 mg (3.92 mmol) sodium hydride are added, and the mixture is warmed to room temperature and stirred for 30 minutes. 580 mg (1.12 mmol) of Example 16A are added as a solution in 6 ml tetrahydrofuran. The reaction mixture is stirred under reflux overnight. The mixture is partitioned between ethyl acetate and 2 N hydrochloric acid, the organic phase is sequentially washed with water and saturated sodium chloride solution, dried over magnesium sulfate and evaporated in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 2:1 → 0:1) and thereafter by RP-HPLC with a water/acetonitrile gradient.
  • Yield: 270 mg (38% of th.) as a mixture of diastereomers
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.21/1.36 (2s, 9H), 1.88/1.92 (2s, 3H), 4.95 (s, 1H), 5.10-5.23 (m, 2H), 5.47/5.51 (2d, 1H), 7.21-7.90 (m, 13H), 8.58/8.61 (2d, 1H) ppm.
    • Example 60 Benzyl 3-{4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}-3-oxopropanoate
  • Figure imgb0087
  • 100 mg (0.16 mmol) of Example 59 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature for 1 hour. Volatiles are evaporated in vacuo and the crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 1:1).
  • Yield: 39 mg (42% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.99 (s, 3H), 3.58 (d, 1H), 3.93 (d, 1H), 5.05 (s, 2H), 5.48 (d, 1H), 7.25-7.40 (m, 4H), 7.48-7.55 (br d, 1H), 7.60-7.73 (m, 4H), 7.80 (d, 1H), 7.86 (d, 2H), 8.55 (d, 1H) ppm.
    • Example 61 2-(Benzyloxy)-2-oxoethyl (4R)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0088
  • 200 mg (0.50 mmol) of Example 6A are dissolved in 2.0 ml dimethylformamide. 456 mg (1.99 mmol) benzyl bromoacetate and 100 mg (1.00 mmol) triethylamine are added, and the mixture is stirred at room temperature for 2 hours. The reaction mixture is partitioned between ethyl acetate and 2 N hydrochloric acid, the organic layer is sequentially washed with water and saturated sodium chloride solution, dried over magnesium sulfate and evaporated to dryness in vacuo. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate 1:1 → 0:1).
  • Yield: 260 mg (95% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 2.05 (s, 3H), 4.74 (s, 1H), 5.12 (s, 1H), 5.41 (d, 1H), 7.28-7.42 (m, 5H), 7.53 (d, 1H), 7.61 (d, 2H), 7.65-7.75 (m, 2H), 7.77-7.86 (m, 3H), 8.45 (d, 1H) ppm.
  • In analogy to the procedure for Example 13A, the following compounds are prepared:
    Example No. Structure Starting material Yield [%] Rt [min] (method) Mass [M+H]+
    62
    Figure imgb0089
         		Example 57 60 5.91(1) 770
    63
    Figure imgb0090
         		Example 58 62 5.58(1) 678
    • Example 64 2-[(tert.-Butoxycarbonyl)amino]ethyl 3-(2-tert.-Butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0091
  • 70 mg (0.12 mmol) of Example 15A and 521 mg (3.23 mmol) tert.-butyl-N-hydroxyethyl carbamate are reacted at 100°C for 150 minutes. The reaction mixture is diluted with acetonitrile and purified using preparative RP-HPLC (eluent: acetonitrile/water gradient).
  • Yield: 41.9 mg (52% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.28 (s, 9H), 1.36 (s, 9H), 2.05 (s, 3H), 3.03-3.18 (m, 2H), 3.80-4.1 (m, 4H), 5.10 (s, 1H), 6.82-6.95 (m, 1H), 7.60-7.93 (m, 8H) ppm.
    • Example 65 2-(2-Oxopyrrolidin-1-yl)ethyl 3-(2-tert.-butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3 ,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0092
  • The title compound is synthesized in analogy to Example 64 from Example 15A using N-(2-hydroxyethyl)-2-pyrrolidone instead of tert.-butyl-N-hydroxyethyl carbamate.
  • Yield: 74% of th.
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.30 (s, 9H), 1.81 (q, 2H), 2.03 (s, 3H), 2.13 (t, 2H), 3.13-3.5 (m, 4H), 3.84 (d, 1H), 4.00-4.20 (m, 3H), 5.52 (s, 1H), 7.60-7.92 (m, 8H) ppm.
    • Example 66 2-(Benzyloxy)-2-oxoethyl 3-(2-tert.-butoxy-2-oxoethyl)-4-(4-cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carboxylate
  • Figure imgb0093
  • The title compound is synthesized in analogy to Example 64 from Example 15A using benzyl hydroxyacetate instead of tert.-butyl-N-hydroxyethyl carbamate.
  • Yield: 32% of th.
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.30 (s, 9H), 2.05 (s, 3H), 3.87 (d, 1H), 4.09 (d, 1H), 4.73 (d, 1H), 5.12 (s, 1H), 5.60 (s, 1H), 7.28-7.41 (m, 5 H), 7.60-7.85 (m, 8H) ppm.
    • Example 67 [6-(4-Cyanophenyl)-4-methyl-2-oxo-5-{[2-(2-oxopyrrolidin-1-yl)ethoxy]carbonyl}-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0094
  • 34.9 mg of Example 65 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Yield: 18 mg (57% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.81 (q, 2H), 2.02 (s, 3H), 2.13 (t, 2H), 3.10-3.55 (m, 4H), 3.72 (d, 1H), 4.00-4.22 (m, 3H), 5.52 (s, 1H), 7.58-7.93 (m, 8H), 12.75 (br s, 1H) ppm.
    • Example 68 tert.-Butyl [6-(4-cyanophenyl)-4-methyl-5-{[(methylsulfonyl)amino]carbonyl}-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0095
  • 100 mg (0.19 mmol) of Example 14A, 36.9 mg (0.39 mmol) methanesulfonamide, 44.0 mg (0.21 mmol) dicyclohexylcarbodiimide and 26.1 mg (0.21 mmol) 4-N,N-dimethylaminopyridine are dissolved in dry dichloromethane (2 ml) and reacted overnight. The reaction mixture is filtered, the filtrate is sequentially washed with 2 M hydrochloric acid, water and saturated ammonium chloride solution, and the organic phase is dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography on silica gel (eluent: cyclohexane/ethyl acetate/acetic acid 50:50:1).
  • Yield: 50 mg (41% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.28 (s, 3H), 1.80 (s, 3H), 3.07 (s, 3H), 3.80 (d, 1H), 4.01 (d, 1H), 5.60 (s, 1H), 7.56-7.95 (m, 8H), 11.70 (br s, 1H) ppm.
  • In analogy to the procedure for Example 68, the following compounds are prepared:
    Example No. Structure Starting materials Yield [%] Rt [min] (method) Mass [M+H]+
    69
    Figure imgb0096
         		Example 14A; 2,2,2-trifluoro-ethanesulfon-amide 71 5.12(1) 661
    70
    Figure imgb0097
         		Example 14A; 4-fluoro-benzene-sulfonamide 43 5.17(1) 673
    71
    Figure imgb0098
         		Example 5A; methanesulfon-amide 6 4.17 (6) 479
    72
    Figure imgb0099
         		Example 5A; 2,2,2-trifluoro-ethanesulfon-amide 76 4.51 (6) 547
    73
    Figure imgb0100
         		Example 5A; 4-cyano-benzenesulfon-amide 67 4.49 (6) 566
    • Example 74 [6-(4-Cyanophenyl)-4-methyl-5-{[(methylsulfonyl)amino]carbonyl}-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0101
  • 45.6 mg (0.08 mmol) of Example 68 are dissolved in 2 ml dichloromethane/trifluoroacetic acid (1:1) and stirred at room temperature for 1 hour. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC with a water/acetonitrile gradient.
  • Yield: 13 mg (31 % of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.28 (s, 3H), 1.78 (s, 3H), 3.11 (s, 3H), 3.69 (d, 1H), 4.10 (d, 1H), 5.62 (s, 1H), 7.52-8.10 (m, 8H), 11.70 (br s, 1H), 12.70 (br s, 1H) ppm.
  • In analogy to the procedure for Example 74, the following compounds are prepared:
    Example No. Structure Starting material Yield [%] Rt [min] (method) Mass [M+H]+
    75
    Figure imgb0102
         		Example 69 41 4.56(1) 605
    76
    Figure imgb0103
         		Example 70 73 4.59(1) 617
    • Example 77 tert.-Butyl [6-(4-cyanophenyl)-5-(hydroxymethyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0104
  • 50 mg (0.13 mmol) of Example 1 are dissolved in 1 ml tetrahydrofuran, 10.8 mg (0.27 mmol) sodium hydride are added, and the mixture is stirred for 15 minutes at room temperature. 27 mg (0.14 mmol) tert.-butyl bromoacetate is added, and the mixture is stirred at room temperature for 1 hour. Saturated aq. ammonium chloride solution is added, and the reaction mixture is diluted with ethyl acetate. The organic phase is washed with water, dried over magnesium sulfate and evaporated to dryness. The crude product is purified by column chromatography over silica gel (eluent: cyclohexane/ethyl acetate).
  • Yield: 17.7 mg (27% of th.)
  • 1H-NMR (200 MHz, DMSO-d6): δ = 1.30 (s, 9H), 1.56 (s, 3H), 3.52 (dd, 1H), 3.62 (dd, 1H), 3.92-4.12 (m, 2H), 4.82 (t, 1H), 5.25 (s, 1H), 7.52-7.80 (m, 6H), 7.88 (d, 2H) ppm.
    • Example 78 3-{4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}propanoic acid
  • Figure imgb0105
  • 45.0 mg (0.057 mmol) of Example 17A und 5.00 mg palladium on charcoal (10%) are suspended in 5 ml ethanol and hydrogenated under 1 atm hydrogen at room temperature for 12 minutes. The reaction mixture is filtered over celite and the residue is washed with ethanol. The filtrate is evaporated to dryness in vacuo and the remainder is heated without solvent at 130°C under an argon atmosphere for 20 minutes. The crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Yield: 9 mg (26% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.53 (s, 3H), 1.92-2.42 (m, 4H), 4.93 (s, 1H), 7.50-7.94 (m, 9H), 12.08 (br s, 1H) ppm.
    • Example 79 ({(4R)-4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}methyl)malonic acid
  • Figure imgb0106
  • 200 mg (0.25 mmol) of Example 19A und 5.0 mg palladium on charcoal (10%) are suspended in 10 ml ethanol and hydrogenated under 1 atm hydrogen at room temperature for 15 minutes. The reaction mixture is filtered over celite and the residue is washed with ethanol. The filtrate is evaporated to dryness in vacuo and the crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Yield: 87 mg (72% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.5 (s, 3H), 2.2 (dd, 2H), 2.6 (dd, 2H), 3.5 (dd, 1H), 5.0 (d, 1H), 7.5 (m, 2H), 7.6-7.7 (m, 4H), 7.8 (d, 1H), 7.9 (m, 2H), 12.8 (br s, 2H) ppm.
    • Example 80 3-{(4R)-4-(4-Cyanophenyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-5-yl}propanoic acid
  • Figure imgb0107
  • 40 mg (0.08 mmol) of Example 79 are heated without solvent at 130°C under an argon atmosphere for 20 minutes. The crude product is purified by column chromatography (silica, eluent: dichloromethane/methanol 20:1).
  • Yield: 36 mg (99% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.5 (s, 3H), 1.9-2.2 (m, 2H), 2.3-2.4 (m, 2H), 4.9 (d, 1H), 7.50-7.7 (m, 6H), 7.8 (d, 1H), 7.9 (m, 2H), 12.1 (br s, 1H) ppm.
    • Examples 81 and 82 4-{(4R)-5-(1-Hydroxyethyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0108
  • 300 mg (0.75 mmol) of Example 18A are dissolved in 5 ml tetrahydrofuran. At 0°C, 28.5 mg (0.75 mmol) lithium aluminium hydride (as 1 M solution in tetrahydrofuran) are added slowly. The dark-red solution is stirred at 0°C for 30 minutes, then water is added. The pH is adjusted to 3-4 with 1 N hydrochloric acid. The crude product is extracted with ethyl acetate and purified and separated by column chromatography (silica, eluent: dichloromethane/methanol 40:1).
    • Example 81 (Diastereomer I):
  • Yield: 15 mg (5% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.2 (d, 3H), 1.6 (s, 3H), 4.6 (m, 2H), 4.9 (d, 1H), 7.4 (m, 1H), 7.5 (m, 1H), 7.7 (m, 4H), 7.8 (m, 2H), 7.9 (d, 1H) ppm.
    • Example 82 (Diastereomer II):
  • Yield: 15 mg (5% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 0.8 (d, 3H), 1.6 (s, 3H), 4.6 (m, 1H), 5.0 (d, 1H), 5.1 (d, 1H), 7.5 (m, 1H), 7.6-7.7 (m, 5H), 7.8 (d, 1H), 7.9 (m, 2H) ppm.
    • Example 83 4-{5-(4-Bromobenzoyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0109
  • 4.23 g (20.74 mmol) N-[3-(trifluoromethyl)phenyl]urea, 2.72 g (20.74 mmol) 4-cyanobenzaldehyde, 5.00 g (20.74 mmol) 1-(4-bromophenyl)butane-1,3-dione and 6.5 g polyphosphoric acid ethyl ester are suspended in 50 ml of tetrahydrofuran. The mixture is stirred at reflux for 20 hours. After cooling down to room temperature, the solvent is removed in vacuo and the residue is purified by column chromatography on silica with cyclohexane/ethyl acetate mixtures as eluent.
  • Yield: 5.32 g (45% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.4 (s, 3H), 5.4 (d, 1H), 7.6-7.9 (m, 12H), 8.4 (d, 1H) ppm.
    • Example 84 tert.-Butyl [5-(4-bromobenzoyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0110
  • 5.32 g (9.85 mmol) of Example 83 are dissolved in 150 ml tetrahydrofuran, and 0.98 g (24.61 mmol) sodium hydride (60% suspension in mineral oil) are added slowly. After stirring for one hour at room temperature, 2.88 g (14.77 mmol) tert.-butyl bromoacetate are added. After stirring at room temperature for one hour, the mixture is quenched with water, the solvent is removed in vacuo and the residue is purified by column chromatography (silica, eluent: cyclohexane/ethyl acetate 10:1, 5:1).
  • Yield: 3.12 g (48% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.3 (s, 9H), 1.4 (s, 3H), 3.9 (d, 1H), 4.1 (d, 1H), 5.6 (s, 1H), 7.7 (m, 7H), 7.8 (m, 5H) ppm.
    • Example 85 [5-(4-Bromobenzoyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-di-hydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0111
  • 100 mg (0.15 mmol) of Example 84 are dissolved in 10 ml dichloromethane and 0.25 ml trifluoroacetic acid, and the mixture is stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Yield: 47 mg (52% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.4 (s, 3H), 3.7 (d, 1H), 4.2 (d, 1H), 5.7 (s, 1H), 7.7 (m, 8H), 7.8 (m, 4H) ppm.
    • Example 86 tert.-Butyl [5-(biphenyl-4-ylcarbonyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)-phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0112
  • 100 mg (0.15 mmol) of Example 84 are dissolved in 5 ml N,N-dimethylformamide under an argon atmosphere, and 19 mg (0.15 mmol) phenylboronic acid, 100 mg (0.31 mmol) cesium carbonate and 5 mg dichloro[bis(triphenylphosphino)palladium are added. The reaction mixture is stirred at 120°C for 18 hours. The product is purified by RP-HPLC using a water/acetonitrile gradient.
  • Yield: 39 mg (39% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.3 (s, 9H), 1.5 (s, 3H), 3.9 (d, 1H), 4.2 (d, 1H), 5.7 (s, 1H), 7.5 (m, 3H), 7.7-7.9 (m, 14H) ppm.
    • Example 87 [5-(Biphenyl-4-ylcarbonyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0113
  • 30 mg (0.05 mmol) of Example 86 are dissolved in 2 ml dichloromethane and 0.07 ml trifluoroacetic acid, and the mixture is stirred at room temperature overnight. Volatiles are evaporated in vacuo and the remainder is purified by RP-HPLC using a water/acetonitrile gradient.
  • Yield: 23 mg (83% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.5 (s, 3H), 3.7 (d, 1H), 4.3 (d, 1H), 5.7 (s, 1H), 7.4-7.5 (m, 3H), 7.6-7.9 (m, 14H) ppm.
    • Example 88 4-{5-(4-Nitrobenzoyl)-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0114
  • 9.85 g (48.27 mmol) N-[3-(trifluoromethyl)phenyl]urea, 6.33 g (48.27 mmol) 4-cyanobenzaldehyde, 10.00 g (48.27 mol) 1-(4-nitrophenyl)butane-1,3-dione and 15 g polyphosphoric acid ethyl ester are suspended in 100 ml of tetrahydrofuran. The mixture is stirred at reflux for 20 hours. After cooling down to room temperature, the solvent is removed in vacuo and the residue is purified by column chromatography on silica with cyclohexane/ethyl acetate mixtures as eluent.
  • Yield: 7.84 g (32% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 1.4 (s, 3H), 5.4 (d, 1H), 7.6 (m, 3H), 7.7 (m, 1H), 7.8 (m, 2H), 7.8 (m, 1H), 7.9 (m, 3H), 8.3 (m, 2H), 8.5 (d, 1H) ppm.
    • Example 89 tert.-Butyl [5-(4-nitrobenzoyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl] acetate
  • Figure imgb0115
  • 5.27 g (10.41 mmol) of Example 88 are dissolved in 150 ml tetrahydrofuran, and 1.04 g (26.02 mmol) sodium hydride (60% suspension in mineral oil) are added slowly. After stirring for one hour at room temperature, 3.04 g (15.61 mmol) tert.-butyl bromoacetate are added. After stirring at room temperature for one hour, the mixture is quenched with water, the solvent is removed in vacuo and the residue is purified by column chromatography (silica, eluent: cyclohexane/ethyl acetate 10:1, 5:1).
  • Yield: 0.16 g (3% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.3 (s, 9H), 1.5 (s, 3H), 3.9 (d, 1H), 4.2 (d, 1H), 5.6 (s, 1H), 7.7 (m, 4H), 7.8-7.9 (m, 6H), 8.3 (m, 2H) ppm.
    • Example 90 tert.-Butyl [5-(4-aminobenzoyl)-6-(4-cyanophenyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0116
  • 160 mg (0.26 mmol) of Example 89 und 5 mg palladium on charcoal (10%) are suspended in 20 ml tetrahydrofuran and hydrogenated under 1 atm hydrogen at room temperature for 18 hours. The reaction mixture is filtered over celite, the filtrate is evaporated to dryness in vacuo and the crude product is purified by RP-HPLC with a water/acetonitrile gradient.
  • Yield: 69 mg (45% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 1.3 (s, 9H), 1.4 (s, 3H), 3.7 (d, 1H), 4.1 (d, 1H), 5.6 (s, 1H), 6.2 (m, 2H), 6.5 (m, 2H), 7.5 (m, 2H), 7.6 (m, 2H), 7.7 (m, 2H), 7.8 (m, 4H) ppm.
    • Example 91 tert. -Butyl [(6R)-6-(4-cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin- (2H)-yl]acetate
  • Figure imgb0117
  • The title compound is prepared from Example 23 according to the procedure described for Example 26.
  • Yield: 108 mg (85% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.90-7.58 (m, 8H), 5.74-5.67 (m, 1H), 4.15-3.85 (m, 2H), 2.30-2.19 (m, 1H), 1.97 (s, 3H), 1.30 (s, 9H), 0.90-0.73 (m, 4H) ppm.
    • Example 92 [(6R)-6-(4-Cyanophenyl)-5-(cyclopropylcarbonyl)-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetic acid
  • Figure imgb0118
  • The title compound is prepared from Example 91 according to the procedure described for Example 30.
  • Yield: 80 mg (89% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 12.62 (br s, 1H), 7.91-7.55 (m, 8H), 5.77 (s, 1H), 4.23-3.70 (m, 2H), 2.32-2.19 (m, 1H), 1.97 (s, 3H), 0.94-0.72 (m, 4H) ppm.
    • Example 93 4-(5-[(2,2-Dimethyl-1,3-dioxolan-4-yl)carbonyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0119
  • To a stirred solution of Example 20A (120 mg, 0.64 mmol), N-[3-(trifluoromethyl)phenyl]urea (109 mg, 0.54 mmol) and 4-cyanobenzaldehyde (84.5 mg, 0.64 mmol) in methyl tert.-butyl ether (5 ml) is added 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (683 mg, 1 mmol). The solution is refluxed overnight under argon, then cooled to room temperature, quenched with water (200 ml) and extracted with methyl tert.-butyl ether (3 x 100 ml). The combined organic phases are washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue is purified by preparative HPLC.
  • Yield: 15 mg (5% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 8.48 (m, 1H), 8.00-7.38 (m, 8H), 5.66-5.40 (m, 1H), 4.99-4.74 (m, 1H), 4.16-3.85 (m, 2H), 1.94 (d, 3H), 1.35-1.11 (m, 6H) ppm.
    • Example 94 4-{5-(Cyclohexylcarbonyl)-3-[2-(diethylamino)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0120
  • To a stirred solution of Example 21 (780 mg, 1.67 mmol) in THF (25 ml) is added sodium hydride (60% dispersion in mineral oil; 653 mg, 2.53 mmol). The mixture is stirred for 1 hour at room temperature, then 2-bromo-N,N-diethylethanamine (653 mg, 2.53 mmol) is added, and the solution is stirred overnight (16 h) at room temperature. The reaction mixture is quenched with methanol (10 ml), concentrated, and the crude product is purified by preparative HPLC.
  • Yield: 175 mg (18% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 7.98-7.50 (m, 8H), 5.71 (s, 1H), 3.66-3.54 (m, 2H), 3.10-3.00 (m, 2H), 2.86-2.76 (m, 1H), 2.69-2.30 (m, 4H), 1.77 (s, 3H), 1.73-1.00 (m, 10H), 0.93 (t, 6H) ppm.
    • Example 95 4-{5-(Cyclopropylcarbonyl)-3-[2-(diethylamino)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0121
  • The title compound is prepared from Example 22 according to the procedure described for Example 94.
  • Yield: 235 mg (59% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 7.93-7.54 (m, 8H), 5.81 (s, 1H), 3.68-3.59 (m, 2H), 3.12-3.01 (m, 2H), 2.60-2.56 (m, 5H), 1.92 (s, 3H), 0.97-0.78 (m, 10H) ppm.
    • Example 96 tert.-Butyl [6-(4-cyanophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0122
  • The title compound is prepared from Example 93 according to the procedure described for Example 26.
  • Yield: 145 mg (62% of th.)
  • 1H-NMR (400 MHz, DMSO-d6): δ = 7.92-7.56 (m, 8H), 5.77 and 5.62 (s, 1H; diastereomers A and B), 4.97 and 4.82 (t, 1H; diastereomers A and B), 4.19-3.83 (m, 4H), 1.96 and 1.93 (s, 3H; diastereomers A and B), 1.34-1.20 (m, 15H) ppm.
    • Example 97 Methyl [6-(4-cyanophenyl)-5-[(2,2-dimethyl-1,3-dioxolan-4-yl)carbonyl]-4-methyl-2-oxo-3-[3-(trifluoromethyl)phenyl]-3,6-dihydropyrimidin-1(2H)-yl]acetate
  • Figure imgb0123
  • The title compound is prepared from Example 93 according to the procedure described for Example 26.
  • Yield: 77 mg (65% of th.)
  • 1H-NMR (300 MHz, DMSO-d6): δ = 7.94-7.55 (m, 8H), 5.81 and 5.66 (s, 1H; 2 diastereomers), 4.99 and 4.87 (t, 1H; 2 diastereomers), 4.35-3.85 (m, 4H), 3.57 and 3.55 (s, 3H; 2 diastereomers), 1.95 and 1.92 (s, 3H; 2 diastereomers), 1.25 (dd, 6H) ppm.
    • Example 98 4-{(4R)-5-(Cyclopropylcarbonyl)-3-[2-(diethylamino)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0124
  • The enantiomers of Example 95 are separated by preparative HPLC on a chiral phase [Daicel Chiralpak AD-H, 5 µm; 250 mm x 20 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 15 ml/min; temperature 25°C; detection 220 nm].
  • Rt = 4.58 min. [Daicel Chiralpak AD-H, 5 µm; 250 mm x 4.6 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 1.0 ml/min; temperature 35°C; detection 220 nm].
    • Example 99 4-{(4R)-5-(Cyclohexylcarbonyl)-3-[2-(diethylamino)ethyl]-6-methyl-2-oxo-1-[3-(trifluoromethyl)-phenyl]-1,2,3,4-tetrahydropyrimidin-4-yl}benzonitrile
  • Figure imgb0125
  • The enantiomers of Example 94 are separated by preparative HPLC on a chiral phase [Daicel Chiralpak AD-H, 5 µm; 250 mm x 20 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 15 ml/min; temperature 25°C; detection 220 nm].
  • Rt = 4.24 min. [Daicel Chiralpak AD-H, 5 µm; 250 mm x 4.6 mm; eluent: 80:20 isohexane/isopropanol with 0.2% diethylamine; flow 1.0 ml/min; temperature 35°C; detection 220 nm].
    • C. Operative examples relating to pharmaceutical compositions
  • The compounds according to the invention can be converted into pharmaceutical preparations as follows:
    • Tablet Composition:
  • 100 mg of the compound of Example 1, 50 mg of lactose (monohydrate), 50 mg of maize starch (native), 10 mg of polyvinylpyrrolidone (PVP 25) (from BASF, Ludwigshafen, Germany) and 2 mg of magnesium stearate.
  • Tablet weight 212 mg, diameter 8 mm, curvature radius 12 mm.
    • Preparation:
  • The mixture of active component, lactose and starch is granulated with a 5% solution (m/m) of the PVP in water. After drying, the granules are mixed with magnesium stearate for 5 min. This mixture is moulded using a customary tablet press (tablet format, see above). The moulding force applied is typically 15 kN.
    • Orally administrable suspension Composition:
  • 1000 mg of the compound of Example 1, 1000 mg of ethanol (96%), 400 mg of Rhodigel (xanthan gum from FMC, Pennsylvania, USA) and 99 g of water.
  • A single dose of 100 mg of the compound according to the invention is provided by 10 ml of oral suspension.
    • Preparation:
  • The Rhodigel is suspended in ethanol and the active component is added to the suspension. The water is added with stirring. Stirring is continued for about 6h until the swelling of the Rhodigel is complete.

Claims (10)

  1. Compounds of general formula (I)
    Figure imgb0126
     , wherein
    A represents a phenyl or a pyridyl ring,
    R1 and R3 each represent hydrogen,
    R2 represents fluoro, chloro, bromo, nitro or cyano,
    R4 represents
    - C1-C4-alkyl which can be substituted by up to two radicals independently selected from the group consisting of hydroxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    - C3-C6-cycloalkylcarbonyl which can be substituted by up to two radicals independently selected from the group consisting of C1-C4-alkyl, hydroxy, oxo, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    - benzoyl which is substituted by one, two or three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, C1-C4-alkyl, trifluoromethyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    - C1-C4-alkoxycarbonyl which is substituted by one or two radicals independently selected from the group consisting of benzyloxy, benzyloxycarbonyl, C1-C4-alkoxy, C1-C4-alkoxycarbonylamino, pyrrolidinyl, piperidinyl and morpholinyl, wherein C1-C4-alkoxy is further substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl, and wherein pyrrolidinyl, piperidinyl and morpholinyl is further substituted by hydroxy, oxo, C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    - furylcarbonyl, oxazolylcarbonyl, thiazolylcarbonyl or pyridylcarbonyl each of which is substituted by one or two radicals independently selected from the group consisting of hydroxy, amino, fluoro, chloro, bromo, C1-C4-alkoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl, and each of which can additionally be substituted by C1-C4-alkyl,
    - mono- or di-C1-C4-alkylaminocarbonyl wherein the alkyl moiety or at least one alkyl moiety, respectively, is substituted by phenyl which for its part can be further substituted by up to three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-akoxycarbonyl and hydroxycarbonyl,
    - piperidinylcarbonyl, piperazinylcarbonyl or morpholinylcarbonyl each of which is substituted by one or two radicals independently selected from the group consisting of C1-C4-alkyl, hydroxy, oxo, C1-C4-alkoxy, C1-C4-alkoxycarbonyl, benzyloxycarbonyl, hydroxycarbonyl, piperidinyl, morpholinyl, pyridyl and phenyl, wherein C1-C4-alkyl is further substituted by hydroxy, C1-C4-alkoxy, C1-C4-alkoxycarbonyl or hydroxycarbonyl, and wherein phenyl can be further substituted by up to three radicals independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, C1-C4-alkyl, hydroxy, C1-C4-alkoxy, trifluoromethoxy, C1-C4-alkoxycarbonyl and hydroxycarbonyl,
    or
    - a group of the formula -C(=O)-NH-SO2-Rb wherein Rb represents C1-C4-alkyl which can be substituted by trifluoromethyl, or Rb represents phenyl which can be substituted by C1-C4-alkyl, fluoro, chloro, bromo, cyano, nitro or trifluoromethyl,
    R5 represents methyl,
    R6 represents hydrogen, C1-C4-alkyl, mono- or di-C1-C4-akylaminocarbonyl, C1-C4-alkylcarbonyl or C1-C4-alkoxycarbonyl, wherein C1-C4-alkyl and C1-C4-alkoxycarbonyl can be substituted with a radical selected from the group consisting of hydroxy, C1-C4-alkoxy, C1-C4-alkoxycarbonyl, hydroxycarbonyl, aminocarbonyl, mono- and di-C1-C4-alkylaminocarbonyl, amino, mono- and di-C1-C4-akylamino,
    or
    R6 represents a moiety of the formula
    Figure imgb0127
     wherein
    Rd is selected from the group consisting of hydrogen and methyl,
    or
    R6 represents a group of the formula -T-U wherein
    T represents a -CH2- group
    and
    U represents
    • phenyl, furyl or oxazolyl each of which is substituted by one or two radicals independently selected from the group consisting of fluoro, chloro, bromo, C1-C4-alkyl and a group of the formula -V-W wherein V represents a bond, a -CH2- group or a -CH=CH- group, and W represents C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    • a group of the formula -C(=O)-NH-SO2-Rf wherein Rf represents C1-C4-alkyl which can be substituted by trifluoromethyl, or Rf represents phenyl which can be substituted by C1-C4-alkyl, fluoro, chloro, bromo, cyano, nitro or trifluoromethyl,
    or
    • a group of the formula -C(=O)-NHRh wherein Rh represents phenyl which can be substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    or
    R6 represents
    - C3-C6-cycloalkyl which can be substituted by C1-C4-alkoxycarbonyl or hydroxycarbonyl,
    or
    - a -CH=CH- group which is substituted by C1-C4-akoxycarbonyl or hydroxycarbonyl,
    R7 represents trifluoromethyl or nitro,
    and
    Y1, Y2, Y3, Y4 and Y5 each represent CH.
  2. Compounds of general formula (I) according to claim 1, wherein R2 is cyano.
  3. Compounds of general formula (IA) according to claim 1
    Figure imgb0128
     wherein
    Z represents CH or N, and
    R1, R3, R4 and R6 have the meaning indicated in any of the preceding claims.
  4. Process for synthesizing the compounds of general formula (I) according to Claim 1 by condensing compounds of general formula (II)
    Figure imgb0129
     wherein A, R1 and R2 have the meaning indicated in Claim 1,
    with compounds of general formula (III)
    Figure imgb0130
     wherein R4 and R5 have the meaning indicated in Claim 1,
    and compounds of general formula (IV)
    Figure imgb0131
     wherein R3, R7, and Y1 to Y5 have the meaning indicated in Claim 1,
    in the presence of an acid or acid anhydride to give compounds of the general formula (IB)
    Figure imgb0132
     wherein A, R1 to R5, R7, and Y1 to Y5 have the meaning indicated in Claim 1,
    optionally followed, in case R6 does not represent hydrogen, by reaction of the compounds of general formula (IB) with compounds of the general formula (V)

            R6*-X     (V),

    wherein
    R6* has the meaning of R6 as indicated in Claim 1, but does not represent hydrogen, and
    X represents a leaving group,
    in the presence of a base.
  5. The composition containing at least one compound of general formula (I) according to Claim 1 and a pharmacologically acceptable diluent.
  6. A composition according to Claim 5 for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes occurring during pulmonary or cardiovascular diseases.
  7. The process for the preparation of compositions according to Claim 5 or 6 characterized in that the compounds of general formula (I) according to Claim 1 together with one or more pharmacologically safe excipient or carrier substances are brought into a suitable application form selected from the group consisting of orally, parenterally, pulmonally, nasally, sublingually, lingually, buccally, rectally, transdermally, conjunctivally, otically application forms or as an implant.
  8. Use of the compounds of general formula (I) according to Claim 1 for the preparation of medicaments.
  9. Use according to Claim 8 for the preparation of medicaments for the treatment of acute and chronic inflammatory, ischaemic and/or remodelling processes occurring during pulmonary or cardiovascular diseases.
  10. Use according to Claim 9, wherein the process is chronic obstructive pulmonary disease, acute coronary syndrome, acute myocardial infarction or development of heart failure.
EP05707386A 2004-02-26 2005-02-15 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors Not-in-force EP1723121B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP05707386A EP1723121B1 (en) 2004-02-26 2005-02-15 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04004314 2004-02-26
EP05707386A EP1723121B1 (en) 2004-02-26 2005-02-15 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
PCT/EP2005/001486 WO2005082864A1 (en) 2004-02-26 2005-02-15 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

Publications (2)

Publication Number Publication Date
EP1723121A1 EP1723121A1 (en) 2006-11-22
EP1723121B1 true EP1723121B1 (en) 2012-07-25

Family

ID=34895952

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05707386A Not-in-force EP1723121B1 (en) 2004-02-26 2005-02-15 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors

Country Status (6)

Country Link
US (1) US8101615B2 (en)
EP (1) EP1723121B1 (en)
JP (1) JP4825194B2 (en)
CA (1) CA2557271C (en)
ES (1) ES2394177T3 (en)
WO (1) WO2005082864A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0302486D0 (en) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
ES2367699T3 (en) * 2004-02-19 2011-11-07 Bayer Pharma Aktiengesellschaft DERIVATIVES OF DIHYDROPIRIDINONE.
CA2557272C (en) * 2004-02-26 2012-09-11 Bayer Healthcare Ag Heterocyclic derivatives
CA2590851A1 (en) * 2004-12-16 2006-06-22 Bayer Healthcare Ag Crystal structure of enzyme and uses thereof
GB0502258D0 (en) * 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
BRPI0614290A2 (en) 2005-08-08 2011-03-22 Argenta Discovery Ltd bicyclo [2.2.1] hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
TW200808771A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
DE102006031314A1 (en) * 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Use of 1,4-diaryl-dihydropyrimidin-2-one derivative for producing a medicament for the treatment and/or prophylaxis of e.g. pulmonary arterial hypertension, chronic-obstructive lung diseases and sleep apnea syndrome
WO2008104752A1 (en) * 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
DE102007019690A1 (en) 2007-04-26 2008-10-30 Bayer Healthcare Ag Use of cyclic substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
DE102007019691A1 (en) 2007-04-26 2008-10-30 Bayer Healthcare Ag Use of acyclically substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
DE102007027800A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted bicyclic heteroaryl compounds and their use
DE102007027799A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted furopyrimidines and their use
DE102007051762A1 (en) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituted pyrrolotriazines and their use
PE20091565A1 (en) 2007-11-06 2009-11-06 Astrazeneca Ab DERIVATIVES OF 2-PIRAZINONE AS INHIBITORS OF NEUTROPHILE ELASTASE
DE102007054786A1 (en) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituted Furopyrimidines and their Use
DE102008022521A1 (en) * 2008-05-07 2009-11-12 Bayer Schering Pharma Aktiengesellschaft 1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use
DE102008052013A1 (en) 2008-10-17 2010-04-22 Bayer Schering Pharma Aktiengesellschaft New 4-(4-cyano-2-thioaryl)dihydropyrimidinone compounds are neutrophil elastase inhibitors useful to treat or prevent e.g. pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute lung injury, or cystic fibrosis
DE102007061766A1 (en) 2007-12-20 2009-06-25 Bayer Healthcare Ag New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system
ES2382143T3 (en) * 2007-12-20 2012-06-05 Bayer Pharma Aktiengesellschaft 4- (4-Cyano-2-thioaryl) dihydropyrimidinones and their use
DE102008007400A1 (en) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituted furans and their use
WO2009149836A1 (en) * 2008-06-09 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Annellated 4- (indazolyl) -1,4-dihydropyridine derivatives and methods of use thereof
DE102009004197A1 (en) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclic fused diaryldihydropyrimidine derivatives and their use
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
DE102009016553A1 (en) 2009-04-06 2010-10-07 Bayer Schering Pharma Aktiengesellschaft Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use
WO2011003604A1 (en) * 2009-07-10 2011-01-13 Bayer Schering Pharma Aktiengesellschaft Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof
CN102639505A (en) 2009-10-02 2012-08-15 阿斯利康(瑞典)有限公司 2-pyridone compounds used as inhibitors of neutrophil elastase
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
DE102010030187A1 (en) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP6408582B2 (en) * 2013-08-28 2018-10-17 バイエル・クロップサイエンス・アクチェンゲゼルシャフト Malonic acid ester derivatives of heteroarylpiperidine and heteroarylpiperazine as fungicides
ES2688600T3 (en) * 2013-11-27 2018-11-05 Sunshine Lake Pharma Co., Ltd. Processes for preparing dihydropyrimidine derivatives and intermediates thereof
USRE47493E1 (en) 2014-02-20 2019-07-09 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
JP2017509665A (en) 2014-04-03 2017-04-06 バイエル ファーマ アクチエンゲゼルシャフト 2,5-Disubstituted cyclopentanecarboxylic acids for the treatment of airway diseases
US20170119776A1 (en) 2014-04-03 2017-05-04 Bayer Pharma Aktiengesellschaft Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
EP3126339A1 (en) 2014-04-03 2017-02-08 Bayer Pharma Aktiengesellschaft 2,5-disubstituted cyclopentane carboxylic acids and use thereof
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) * 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
AU2016232270B2 (en) 2015-03-18 2020-09-03 Ph Pharma Co., Ltd. Method for producing (4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile
AR113888A1 (en) 2017-11-17 2020-06-24 Bayer Ag SUBSTITUTE MACROCYCLIC INDOLE DERIVATIVES
EP3759073A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Sulfonamide derivates as nlrp3 inhibitors
US11530200B2 (en) 2018-03-02 2022-12-20 Inflazome Limited Compounds
WO2019166627A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
WO2019166629A1 (en) * 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US11884645B2 (en) 2018-03-02 2024-01-30 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
US20220354833A1 (en) 2019-09-17 2022-11-10 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
CN118265527A (en) 2021-10-20 2024-06-28 美莱奥生物制药第四有限公司 Neutrophil elastase inhibitors for the treatment of fibrosis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214053D0 (en) * 1992-07-02 1992-08-12 Ici Plc Heterocyclic amides
DE60214428T2 (en) * 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-DIHYDRO-1, 4-DIPHENYLPYRIDINE DERIVATIVES
NZ538670A (en) 2002-09-10 2007-01-26 Bayer Healthcare Ag Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
GB2392910A (en) * 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
WO2005037799A1 (en) 2003-10-16 2005-04-28 Cytokinetics, Inc. Compounds, compositions, and methods
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
ES2367699T3 (en) * 2004-02-19 2011-11-07 Bayer Pharma Aktiengesellschaft DERIVATIVES OF DIHYDROPIRIDINONE.
CA2557272C (en) * 2004-02-26 2012-09-11 Bayer Healthcare Ag Heterocyclic derivatives

Also Published As

Publication number Publication date
EP1723121A1 (en) 2006-11-22
ES2394177T3 (en) 2013-01-23
CA2557271C (en) 2012-08-21
US20080064704A1 (en) 2008-03-13
WO2005082864A1 (en) 2005-09-09
CA2557271A1 (en) 2005-09-09
JP2007524696A (en) 2007-08-30
JP4825194B2 (en) 2011-11-30
US8101615B2 (en) 2012-01-24

Similar Documents

Publication Publication Date Title
EP1723121B1 (en) 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
US7893073B2 (en) Heterocyclic derivatives
US8173665B2 (en) I-pheny 1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use
US7687510B2 (en) Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes
US7691854B2 (en) Dihydropyridine derivatives for use as human neutrophil elastase inhibitors
EP1554246B1 (en) Dihydropyridinone derivatives as hne inhibitors
EP1720857B1 (en) Dihydropyridinone derivatives
JP4708025B2 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060926

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AG

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT

17Q First examination report despatched

Effective date: 20091130

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Ref country code: AT

Ref legal event code: REF

Ref document number: 567648

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120815

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602005035267

Country of ref document: DE

Effective date: 20120913

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20120725

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 567648

Country of ref document: AT

Kind code of ref document: T

Effective date: 20120725

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

Effective date: 20120725

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2394177

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20130123

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121125

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121126

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121026

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20130426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20121025

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602005035267

Country of ref document: DE

Effective date: 20130426

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130215

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20120725

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130215

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20050215

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160901 AND 20160907

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20170126

Year of fee payment: 13

Ref country code: DE

Payment date: 20170207

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20170215

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20170221

Year of fee payment: 13

Ref country code: ES

Payment date: 20170127

Year of fee payment: 13

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005035267

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20180215

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20181031

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180901

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180228

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180215

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20190801

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180216